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Melanocytic neoplasia is a multifaceted process involving a complex interplay of genetic and environmental 
factors. Despite recent advances, the aetiology and pathogenesis of melanocytic neoplasms remains unclear and 
the anatomical location and state of differentiation of the initiating cell remains to be elucidated. Traditional 
models propose melanoma arises from an epidermal melanocyte which passes through defined stages of 
increasing atypia due to the accumulation of mutational events. The newly proposed tumour stem cell 
hypothesis, however, advocates melanoma may arise from a mutated tissue-resident precursor cell, and not from 
a terminally differentiated melanocyte. The overall aim of this study was to investigate whether benign naevi 
contain cells with a stem cell-like phenotype, and to examine the question of whether these might be stem cell 
precursors of malignant melanoma. Ten formalin-fixed and paraffin embedded human naevus biopsy samples, 
of five different naevus subtypes, were systematically re-evaluated by direct immunofluorescence first, to 
understand the lineage of a “naevus” cell, and second, to evaluate whether mela ocytic naevi may originate 
from a precursor cell and not via de-differentiation from an epidermal melanocyte. For phenotypic 
characterisation, results were highly suggestive of a melanocytic lineage with 85.36% of naevus cells staining 
positively for the melanocyte specific differentiation antigen, Melan-A, as determined by a semi-quantitative 
analysis. Yet, these cells showed important morphological variations and were distinct from differentiated 
epidermal melanocytes. Furthermore, although studies have suggested regional variations in naevi and a 
possible Schwann cell lineage, there was no evidence in support of a Schwann cell phenotype of naevus cells in 
this study. Secondly, precursor markers were identified in all naevus subtypes analysed, thereby convincingly 
demonstrating the presence of precursor cells within naevus tissue. The majority of positively labelled cells 
localised to the epidermal compartment (72.72%) and this was similar for all three markers analysed: OCT4 
(77.22%), NANOG (63.72%) and p75 (57.15%). Interestingly, dysplastic naevi showed a large proportion of 
OCT4+ cells (5.81%), which was by far the greatest proportion of any precursor marker identified in this study. 
As dysplastic subtypes are associated with an increased risk of melanoma development, this may imply an 
increased stem cell component confers this risk. Thirdly, analysis with the proliferation marker Ki-67 revealed 
the epidermal compartment contained the majority of dividing naevus cells (76.17%), thereby supporting an 
epidermal origin of naevi. Since the majority of precursor cells identified were within the epidermal 
compartment, this may suggest precursor cells drive naevus development, in support of the tumour stem cell 
hypothesis. In addition, the predominance of these precursor cells within the interfollicular epidermis may aid in 
identifying a potential stem cell niche. However, no precursor cells were noted in the normal intervening 
interfollicular epidermis or dermis of naevi, or in the epidermis or dermis of normal human skin, as may have 
been expected. In conclusion, the presence of stem cell markers in naevus tissue supports the hypothesis that at 














1.1 The melanocyte 
Melanocytes are dendritic, pigment-producing cells that are located in the basal layer of the epidermis, the hair 
bulb and the uveal tract of the eye where they play a role in protection against the harmful effects of ultraviolet 
radiation, as well as skin, coat and eye pigmentation. Melanocytes are also found in the inner ear, heart and 
meninges where they are thought to be important in the normal development and functioning of these organ 
systems, as abnormalities of melanin and/or melanocytes are associated with functional impairments, such as 
hearing loss, atrial arrhythmias and neurodegenerative conditions respectively. Although the specific functions 
of melanin in these organs remain under investigation, melanin is thought to function as a biological reservoir 
for substances with cationic properties, such as calcium, iron, copper and magnesium, allowing their storage 
release and exchange (Nordlund et al, 2006; Tolleson et al, 2005), to play a role in the metabolism of certain 
oto- and neuro-toxic drugs (Larsson, 1993; Nordlund et al, 2006; Hu et al, 2002), as well as having a proposed 
vasomotor function (Savin, 1965). Additional roles for melanin in the skin are therefore under investigation. 
 
In human skin, melanocytes reside in the basal layer of the epidermis at a frequency of around one in every ten 
basal cells. They extend cytoplasmic projections, known as dendrites, laterally and upward between surrounding 
keratinocytes. Approximately 36 keratinocytes associate with a single melanocyte, forming the “epidermal-
melanin unit” (Fitzpatrick and Breathnach, 1963). This organisational relationship forms an important structural 
unit, allowing for adequate melanin transfer. It also forms an important functional unit whereby keratinocytes 
regulate melanocyte proliferation, dendricity and rate of melanin production and transfer. This is mediated via 
direct cell contact by cell-to-cell adhesion molecules, as well as paracrine signalling molecules such as 
cytokines, growth factors and hormones. Melanocytes produce the pigment melanin in membrane-bound 
organelles known as melanosomes and transfer these melanosomes via their dendrites to associated 
keratinocytes. Transferred melanosomes aggregate on the sun-exposed surface of the keratinocyte nucleus, 
forming an umbrella-like array that protects the underlying DNA from ultraviolet radiation. It is the 
characteristics of these melanosomes, such as number, size, and degree of melanisation, type of melanin, 
distribution and rate of degradation in the keratinocytes which determines human skin colour and susceptibility 
to ultra-violet radiation (UVR), while the absolute number of melanocytes is similar for both sexes and all races. 
Abnormalities of melanocyte development and/or migration, or in the processes of pigment production and/or 
transfer, leads to a wide range of hyper- or hypo-pigmentary disorders, and alters susceptibility to sun induced 
malignancies.  
 
1.2 Melanocyte embryology and development of the neural crest 
The embryological origin of melanocytes has been widely studied and current opinion holds that melanocytes 













embryo by Wilhem His in 1868. At the time of neural tube formation, a subpopulation of cells at the roof of the 
neural tube delaminates from the neuroepithelium and, under the influence of bone morphogenic protein (BMP) 
and Wnt signalling, undergoes subsequent epithelial to mesenchymal transition to form the neural crest. Neural 
crest stem cells (NCCs) are a transient, highly migratory population of multipotent stem cells and give rise to 
diverse derivatives, including peripheral neurons, glial cells, adrenal medulla, cardiac cells and melanocytes. 
Whether NCCs reflect a population of cells with multiple differentiation abilities (Dupin et al, 2007; as reviewed 
by Le Douarin et al, 2008), or whether the neural crest is composed of a variety of different, yet already 
committed cells (as reviewed by Achilleos and Trainor, 2012; Andersson, 1997; Gilbert, 2000) remains under 
debate.  
 
Neural crest cells migrate and differentiate along two known pathways (Figure 1): (i) early delaminating neural 
crest cells follow the ventral pathway of migration and give rise to the developing peripheral nervous system 
(PNS) and its supporting Schwann cells; and (ii) late migrating cells follow the dorsolateral pathway of 
migration and give rise to melanocytes. Melanocyte migration is supported by a number of experiments in avian 
and mouse embryos, which demonstrate that melanoblasts emerge from the dorsal neural crest and migrate 
dorsolaterally between the ectoderm and dermamyotome before moving ventrally to reach the basal layer of the 
epidermis and hair follicles (reviewed in Adameyko et al, 2009). These so-called founder melanoblasts then 
undergo clonal expansion to populate the overlying epidermis and cycling hair follicles. 
 
 
Figure 1: Diagrammatic representation of neural crest migration pathways in the developing embryo (red arrows) 
and their associated progeny (green underline) (Sakai and Wakamatsu, 2005). 
 
Neural crest formation, and the subsequent migration and differentiation of NCCs along one of the above 
pathways, is marked by the expression of various transcription factors which form a highly organized 
transcriptional regulatory network. Transient, premigratory NCCs have been shown to express forkhead box D3 
(FOXD3), paired box 3 (PAX3) and the SRY (sex determining region Y)-box (SOX) transcription factors 
SOX8, SOX9 and SOX10 (as reviewed by Le Douarin et al, 2008; Thomas et al, 2008), all of which have been 













differentiation by activating downstream transcription factors. Of these, SOX10 plays an important role in the 
developing PNS in the control of Schwann cell differentiation and myelination (reviewed by Ernfors, 2010). 
Expression is maintained in mature Schwann cells where it plays a key role in preserving a functional 
myelinating phenotype (Bremer et al, 2011). SOX10 is also expressed in migrating melanoblasts and has been 
shown to be strongly and widely expressed in normal human skin melanocytes (Agnarsdottir et al, 2010). 
SOX10, together with PAX3, regulates the promoter of Micropthalmia-associated transcription factor (MITF), a 
transcription factor relatively specific for melanocyte lineage (discussed below). In addition, SOX10 activates 
the tyrosinase enhancer, thereby directly contributing to tyrosinase gene expression in developing melanocytes 
(Murisier et al, 2007).  
 
Micropthalmia-associated transcription factor is a member of the Myc-related family of basic helix-loop-helix 
leucine zipper transcription factors and is considered the master regulator of melanocyte fate determination. It is 
consistently the first marker identifying melanoblasts in the developing embryo (reviewed by Ernfors, 2010) and 
expression is maintained in normal human skin melanocytes (Levy et al, 2006). As mentioned above, MITF is 
activated by cell-type-specific effectors, such as PAX3 and SOX10 and has a number of melanocyte-specific 
transcriptional targets, including tyrosinase (TYR), tyrosinase-related protein 1 (TRP1), tyrosinase-related 
protein 2 (TRP2), PMEL17 (silver or gp100) and Melan-A (also known as MART-1, melanoma antigen 
recognized by T cells) (discussed in section 1.5 below).  
 
A further important marker of neural crest development is the low-affinity nerve growth factor receptor, p75 
(also known as p75NTR, p75NGFR and CD271). P75 is one of the receptors for the neurotrophins, a family of 
growth factors important in survival and differentiation of diverse cell types within the developing neural crest 
and PNS (Lewin and Baarde, 1996).  In the neural crest, p75 is expressed in NCCs prior to commitment to either 
melanoblast or Schwann cell fate and thus does not distinguish between glial and melanocyte lineages at the 
level of the neural crest. P75 expression is retained in committed Schwann cell precursors and in mature 
Schwann cells of peripheral nerves (Liang and Johansson, 1998). As melanocyte precursors migrate from the 
neural crest, they acquire the expression of melanocyte specific markers and lose the expression of p75. This 
receptor has not been shown to be re-expressed in mature melanocytes (Trejo et al, 2002) and thus, in 
melanocytes, p75 expression is specific for a precursor phenotype.  
 
1.3 A novel pathway of melanoblast migration 
As discussed above, precursor cells exit the neural crest and travel along one of the aforementioned pathways. 
The exact course and anatomical relationships of these migrating cells, however, has not been clearly 
demonstrated. Also, it has been observed that some ventral melanoblasts appeared to populate the skin at earlier 
time points than can be explained by the arrival of migrating precursor cells of the late-migrating dorsolateral 













expression of key transcription factors, MITF and SOX10, in chick embryo NCCs. Neural crest cells of the 
dorsolateral pathway showed positive MITF and SOX10 expression, as would be expected. Similarly, migrating 
NCCs of the ventral pathway showed positive SOX10 expression and occurred in close association with 
developing peripheral nerves. Surprisingly, however, some of these ventrally migrating cells co-expressed 
MITF, which suggests precursor cells in association with developing peripheral nerves may be an alternate 
source of skin melanocytes. To test this hypothesis, ablation experiments were performed on chick embryos 
using a green fluorescent protein (GFP) expressing construct for NCC tracing. Results showed that ablation of 
both the dorsal and ventral pathway resulted in a dramatic loss of cutaneous melanocytes; however, ablation of 
the dorsal pathway alone did not quantitatively affect numbers of melanoblasts in the ventral limb bud. Lineage 
tracing of GFP NCCs showed neural crest-derived Schwann cell precursors of the ventral pathway as an origin 
of skin melanocytes. This provides new evidence for a ventral pathway of melanoblast migration, and 
importantly, implies a common progenitor cell of both Schwann cells and skin melanocytes persists after exiting 
the neural crest. It could be hypothesised that some progenitor cells may persists in adult tissues and retain a 
multipotent phenotype; and, when stimulated could give rise to either melanoblasts or cells of a Schwann cell 
lineage.  
 
1.4 Neural crest development using experimental models of human origin 
As human embryos are difficult to obtain, there is little information on neural crest pathways in human 
development. To address this issue, Thomas et al (2008) cultured NCCs from human embryos (hNCC), 
Carnegie stages (C) 10 and C14. They found that cultured hNCCs remained euploid and morphologically 
unchanged after more than 20 passages. Using a serial analysis of gene expression (SAGE) technique, they 
reported the expression of classical transcription factors FOXD3, PAX3, SOX9, SOX10 and TWIST1, as well 
as signalling molecules or the membrane-bound receptors NESTIN, p75, endothelin receptor type B (EDNRB), 
platelet-derived growth factor B (PDGFB) and platelet derived growth factor receptor β (PDGFRβ). Of 
particular interest, they noted that the transcriptional profile of some hNCCs was similar to that of human 
embryonic stem (hES) cells and showed positive expression of pluripotency markers SOX2, NANOG and POU 
class 5 homeobox 1 (POU5F1, OCT3, OCT4; hereafter referred to as OCT4). This suggests that a subset of 
neural crest stem cells retains expression of pluripotency markers and thus, the simultaneous expression of 
SOX2, NANOG and OCT4 is not sufficient to confer an embryonic stem cell identity.  In agreement with this, a 
number of studies have derived neural crest-like cells from postnatal tissue niches which, when cultured, contain 
a subset of cells with expression profiles consistent with both embryonic and neural crest lineage. These subsets 
of cells have been identified as NCCs which may retain stem cell properties and include skin-derived precursor 
cells from mouse and human dermal papilla (Fernandes and Miller, 2009; Li et al, 2009; Toma et al, 2005), 
epidermal NCCs from the mouse hair follicle bulge (Sieber-Blum et al, 2006; Sieber-Blum and Hu, 2008), 
palatum-derived NCCs of Wistar rats (Widera et al, 2009) and NCCs derived from mouse corneal limbus 













eventual fate restriction, while a subset of NCCs may reside in certain postnatal niches and retain a multipotent 
phenotype. It is also possible that this subpopulation consists of committed NCCs which are able to re-attain a 
multipotent fate if required or if subject to micro-environmental alterations, including in vitro conditions. 
 
1.5 Fate of melanoblasts on reaching the dermis 
Following the migration of neural crest cells into the dermis, by either the dorsolateral or ventral pathways as 
discussed above, melanocyte precursors migrate ventrally to reach the basal layer of the epidermis and hair 
follicles. In humans, immunohistochemical staining has shown that melanoblasts first appear in the dermis at 6-
8 weeks gestational age (Gleason et al, 2008; Holbrook et al, 1989) and express melanocyte specific markers 
MITF, Melan-A and human melanoma black (HMB45) (Melan-A is specific to skin and retinal melanocytes and 
thus a useful marker for melanocytic tumours, while HMB45 is a pre-melanosomal, transmembrane protein of 
undetermined function which detects melanoblasts/early melanocytes and melanoma cells, but not normal 
melanocytes). These precursor cells then migrate into the epidermis by 10 weeks gestational age, where they are 
observed to localise to the basal layer and have pre-melanosomes as seen by direct electron microscopy and 
their reaction with reduced silver (Zimmerman and Becker, 1959). Interestingly, the number dermal 
melanocytes, as detected by MART-1 and MITF staining, outnumbered those that ultimately localised to the 
epidermis and this likely results from programmed cell death, or apoptosis, as is consistent with normal 
developmental biology. The suggestion, however, that some dermal precursors may be retained within the 
dermis and persist into adult life cannot be excluded.  
 
1.6 Disorders of melanocytes: hyperpigmentary and proliferative disorders  
The final destination for melanocyte migration within the skin is the basal layer of the epidermis. Here, 
melanocytes produce the pigment melanin which confers skin colour and protects the skin from ultraviolet 
radiation as discussed previously. There are two broad categories of melanocytic disorders: those resulting in an 
increase in skin pigmentation, due to an increase in pigment and/or an increase in melanocyte number; and those 
resulting in a decrease in skin pigmentation, due to an absence or decrease in melanocyte number and/or 
function (Freedberg et al, 2003).  
 
Disorders of melanocytes which result in areas of increased pigmentation are broadly sub-grouped into simple 
hyperpigmentary disorders, which include lesions such as the common freckle and solar lentigo, and neoplastic 
disorders, which comprise benign melanocytic naevi and malignant melanoma. The simple hyperpigmentary 
disorders result from an increase in melanin synthesis and transfer to basal keratinocytes. This gives the clinical 
appearance of a well-defined, level area of increased pigmentation, and is generally dependent on local 
environmental factors, such as solar radiation. There is usually little or no proliferation of melanocytes and, if 
proliferation does occur, this is limited and melanocytes retain their linear arrangement along the basement 













These melanocytes have a normal dendritic phenotype which allows transfer of melanin to surrounding 
keratinocytes and/or other cells, such as dermal macrophages (melanophages). 
 
Proliferative or neoplastic disorders on the other hand are characterized by an abnormal proliferation of cells and 
an associated disruption in normal anatomical relationships with surrounding keratinocytes and the underlying 
basement membrane. This proliferation is typically independent of local environmental signals. Neoplastic cells 
are not limited to the epidermal compartment, but may also be located in the dermis or both (Figure 2c). 
Neoplastic cells are often deficient in melanogenesis and may not exhibit dendrites, so that when melanin is 
produced, it is typically retained in their cytoplasm.  
 
 
Figure 2: Histological features of simple hyperpigmentary and neoplastic disorders of melanocytes: 2a: Normal skin 
showing solitary melanocytes along the dermo-epidermal junction at a frequency of about 1 melanocyte to 4-10 basal 
keratinocytes. b: Melanocytic hyperplasia occurring in sun-damaged skin showing a limited proliferation of basal 
melanocytes which preserve their normal anatomical relationships with the basement membrane and surrounding 
keratinocytes, as well as exhibit a dendritic phenotype (images: Carlson et al, 2009). c: Neoplastic proliferation of 
melanocytes, occurring in clusters or nests. There is an associated loss of normal relationships with neighbouring 
keratinocytes and basement membrane. Dendrites are not seen (own image).  
 
1.6.1 The “multiple-hit” hypothesis of neoplasia 
Neoplasia, in general, is thought to arise from a complex interplay of genetic and environmental factors. The 
basic steps are initiation, promotion, progression and, occasionally, resolution. Initiation involves a mutational 
event, which primes the cell to respond abnormally to normal growth signals, or previously sub-threshold 
signals. These mutations are within oncogenes, which promote growth, or within tumour suppressor genes, 
which then allow the cell to proceed through the cell cycle unchecked. This so-called primed cell is now 
susceptible to further insult, usually environmental, and promotion occurs when this primed cell is activated and 
begins to proliferate. Abnormal proliferation is sustained by the underlying initiating mutation, and eventual 
autonomy from surrounding signals leads to neoplastic growth, invasion and metastasis (Cotran et al, 1994; 
Freedberg et al, 2003; Rippey, 1994). For some tumours, such as colon carcinoma, the sequential steps 
contributing to carcinogenesis are well documented and widely accepted. However, the exact processes in 














1.6.2 Benign melanocytic naevi 
The melanocytic naevus, or common mole, is a benign neoplastic proliferation thought to arise from epidermal 
melanocytes. Common (banal) naevi appear as small, round to oval nodules with uniform colour and a regular 
border. They characteristically first appear around one year of age, peak in number during the second or third 
decade of life and then decrease or disappear by the seventh to ninth decade (Kincannon and Boutzale, 1999). 
Banal naevi are broadly sub-grouped according to their histological characteristics as outlined in Table 1.  
 
 
        Table 1: Classification of benign melanocytic naevi (adapted from McKee et al, 2005) 
 
1.6.2.1 Histological features of benign melanocytic naevi 
Histologically, benign neavi consist of small, well-circumscribed proliferations or “nests” of cells, termed 
“naevomelanocytes”, which may be located in the epidermis, dermis or both. These so called 
“naevomelanocytes” or “naevus” cells are thought to represent a type of melanocyte but the exact relationship 
between the two cell types is still under debate, and will be further discussed below. Nests at the dermo-
epidermal junction are round to oval in shape, tend to localise to the tips of the rete ridges and are usually 
equidistant from one another (see Figure 21a, 21b, Results section 3.3.1). As nests descend through the dermis, 
they may be seen to decrease in size and discrete nests may be replaced by singly dispersed cells, features 
referred to in histological terms as “maturation”. Naevus cells in the deeper dermis may also show a smaller, 
spindle-shaped morphology, wavy or s-shaped nuclei and align in vertical cords within loosely woven collagen 
bundles. In addition, these cells may stain negatively for melanocyte markers Melan-A and HMB-45, stain 
positively for Schwann cell antigens S100 or p75 (Barnhill et al, 2004; Freedberg et al, 2003) and may not 
express tyrosinase activity or contain melanosomes (Mishima, 1965; Winnepenninkx and van den Oord, 2004). 
Naevi exhibiting these features are referred to as neurotised or neural naevi as these features are typical of 













varying degrees of architectural and/or cellular atypia, with merging of epidermal nests and fusion of adjacent 
rete ridges (see Figure 21e, 21f, Results section 3.3.1). The cytological atypia may resemble a melanoma. 
 
1.6.2.2 Existing theories on the aetiopathogenesis of melanocytic naevi 
As briefly mentioned above, the precursor cell, and subsequent pathogenesis, of a “naevus” cell remains to be 
fully understood and has, in fact, been debated for over one hundred years. The term “melanocytic naevus”, 
itself, implies a relationship exists between a melanocyte and a naevus cell and in agreement with this a number 
of authors argue for a naevus cell as originating from an epidermal melanocyte, which has undergone specific 
alterations in cellular transcription pathways leading to abnormalities in proliferation, differentiation and 
senescence. Others, however, propose a naevus cell as a distinct cellular lineage. Since most available data on 
melanocytic naevi consists of static, cross-sectional analyses from naevus biopsy specimens, the step wise 
evolution of naevi remains undefined and evidence to support existing hypotheses is limited. A number of 
hypotheses have been proposed and these will be outlined below. 
 
Unna first proposed the theory of “Abtropfung” in 1893, whereby it was hypothesised that melanocytic naevi 
develop from a differentiated epidermal melanocyte with the subsequent “dropping off” of these cells into the 
dermis. This theory describes the sequential development of junctional, compound and, finally, intradermal 
naevi. Evidence in support of this hypothesis is the observation that the majority of naevi in childhood are 
junctional and/or compound, while those arising in adolescents and young adults are predominantly intradermal 
(McKee et al, 2005). This remains the most widely accepted theory to date and is the hypothesis on which 
Clark’s model of melanoma progression, the best accepted model of melanoma development, is based (Figure 3 
below). Many years later, following the observation that naevus cells in the epidermis and superficial papillary 
dermis resemble epithelial cells and demonstrate positive tyrosinase activity, while those in the middle and deep 
dermis show features consistent with neurotisation, as discussed previously, Masson (1951) proposed the “Dual 
origin of naevi”, where he suggested that the junctional component of naevi arises from epidermal melanocytes, 
while the intradermal component arises from Schwann cells.  
 
In opposition to the theory of an epidermal origin of naevi, Kawamura (1956) introduced the concept that 
naevus cells may result from embryonically misdirected cells of the neural crest. He proposed these misdirected 
cells retain the ability to differentiate along both melanocytic and Schwannian lineage, which may well result in 
the dual phenotype of cells observed in certain naevi. Following this, Mishima (1965) proposed the term 
“nevoblast”, where he described an already committed neural crest-derived precursor cell, of either melanocyte 
or Schwannian lineage, resident in the post-natal dermis which, when recruited, proliferates to give rise to a 














The concept of naevi arising from a dermal precursor cell and not an epidermal melanocyte was further 
supported by Cramer (1984) who proposed the theory of “Hochsteigerung” or, literally, “upward climb”. Here, 
Cramer proposed that naevi may originate from neural crest stem cells which are arrested in normal embryonic 
migratory pathways. It was hypothesised that neural crest stem cells may migrate along developing peripheral 
nerve sheaths, first into the dermis and then into the epidermis. If these multipotent precursor cells are retained 
within the dermis due to incomplete migration and, if subject to genetic or environmental aberrations, they may 
give rise to “naevus cells”. In agreement with this, studies have convincingly shown that melanocytes first 
appear in the dermis before populating the overlying epidermis (Gleason et al, 2008; Hulley et al, 1991). And, as 
discussed previously, it has recently been demonstrated that a substantial number of skin melanocytes are 
derived from multipotent Schwann cell precursors of developing peripheral nerves (Ademeyko et al, 2009). 
Persistence of some precursor cells within the dermis may occur and thus be a potential postnatal niche of neural 
crest stem cells.  
 
Lastly, the concept of a melanocytic naevus as a hamartoma has been proposed. A hamartoma is a benign, focal 
malformation of normal tissue elements, which grow at the same rate as surrounding tissue, but grow in a 
disorganised mass, and are commonly found incidentally in the lung. Other organs affected include the heart, 
central nervous system, skin and kidney, and these are seen in various genetic syndromes, such as tuberous 
sclerosis. The demonstration, however, that some naevi are clonal (Hui et al, 2001), and do not simply represent 
an increased proliferation of normal melanocytes and associated epidermal structures, has limited the acceptance 
of this hypothesis. Congenital naevi exhibit distinct histological features and have been considered by many to 
be true hamartomas. For this reason congenital naevi are not considered within the scope of this thesis. 
 
1.6.3 Malignant melanoma 
Melanoma is a malignant proliferation of cells thought to arise from epidermal melanocytes. Four distinct 
subtypes exist, as outlined in Table 2. Unlike benign naevi, a melanoma is characterised histologically by 
cellular and architectural atypia.  Nests at the dermo-epidermal junction are often elongated or irregular in 
shape, and distort the rete ridges. Maturation of cells in the deep dermis is often not observed (as described for 
naevi) and melanocytes may be seen to invade adnexal structures. Inflammatory infiltrates are often seen, and 
associated clinical features, such as ulceration, may be present. Malignant cells may acquire the potential to 
metastasize, whereby they migrate from the primary tumour and grow autonomously at a distant site. This 














        Table 2: Classification of malignant melanoma (adapted from Freedberg et al, 2003). 
 
1.6.3.1 The aetiopathogenesis of melanoma: are naevi and melanoma a continuum of the same process? 
Like melanocytic naevi, the cell of origin and subsequent pathogenesis of a melanoma remains to be fully 
understood. The most widely accepted model for the aetiopathogenesis of melanoma was described by Clark in 
1984. This hypothesis proposes that melanomas arise from epidermal melanocytes which pass through stages of 
increasing atypia due to the accumulation of mutational events (Figure 3). This model depicts an epidermal 
melanocyte which, following a mutational event, proliferates to form a benign naevus. Additional genetic or 
environmental insults allow for the progression o  a benign naevus to a dysplastic naevus, and finally a 
melanoma. The resultant melanoma first exhibits a radial growth phase, where cells are limited to the epidermis 
and superficial dermis, before exhibiting a vertical growth phase where cells invade the deeper dermis. Cells 
finally acquire the ability to migrate out of the dermis, resulting in a metastatic melanoma, the concluding step 
in melanoma evolution (Clark et al, 1984; Herlyn et al, 1985, 1987). This hypothesis is in agreement with 
Unna’s theory of naevus development (discussed previously) and provides a model on which melanomas are 
staged today. This theory is based on the concept that naevi are direct precursor lesions to melanoma; and 
indeed, the presence of numerous naevi, dysplastic naevi and large (>20cm) congenital naevi are identified as 
risk factors for the development of a melanoma. This model is also based on the pathological risk of melanoma, 
where those limited to the epidermis, or “in situ” tumours, are considered low risk due to “early” detection, 
















Figure 3: Biologic Progression of melanoma: Hypothesised evolution and progression of an epidermal melanocyte to a 
metastatic melanoma. 
 
This step-wise theory of carcinogenesis is a well accepted and plausible model of melanoma development, and it 
neatly ties together the evolution of benign naevi and melanoma. However, clinical information does not always 
support this hypothesis. It has previously been reported that a number of melanomas appear to arise de novo, in 
previously appearing normal skin. In fact, it has been reported that 70-80% of cutaneous melanomas do not 
evolve from an identified precursor lesion (Kelly et al, 1997; Lucas et al, 2003).  
 
The difficulty in understanding melanoma aetiology and pathogenesis is that, like naevi, most available data 
consists of static, cross-sectional analyses. In addition, the natural history of naevi is difficult to study. Many 
atypical or suspicious naevi, which may well have progressed to malignant melanoma with time, are removed to 
reduce the risk of melanoma transformation and thus the true rate of melanoma evolution in a pre-existing 
naevus may be under-represented. Similarly, in patients presenting with established melanoma, ascertaining the 
presence or absence of a precursor lesion is usually dependent on patient history alone. It is often difficult to 
objectively establish whether the lack of a precursor lesion was simply due to the patient not noticing a pre-
existing naevus, or whether the presence of a noted pre-existing naevus was in an actual fact a melanoma from 
the outset. A more objective method would be to determine the presence or absence of naevus tissue within a 
melanoma biopsy, but whether the naevus preceded the melanoma, or whether the melanoma developed areas of 
well-differentiated, naevus-like areas cannot be evaluated. The possibility of both lesions arising simultaneously 
should also be considered.  
 
1.6.3.2 The natural history of naevi: clues to melanoma evolution? 
In an attempt to better understand the aetiology and pathogenesis of melanoma, and to obtain more information 
on the natural history of naevi, Tucker et al (2002) prospectively followed 844 members of melanoma-prone 













Sequential documentation of skin lesions was performed by regular clinical examinations and serial 
photographs. Suspicious or changing lesions were biopsied and the histology reviewed. This study reports three 
central results with regards to the natural history of naevi and melanoma evolution. 
 
Firstly, individuals of melanoma-prone families were found to have several hundred naevi (some exceeding 
500) and multiple clinically atypical naevi. The vast majority of these banal and dysplastic naevi remained 
stable or regressed over time. This suggests that multiple naevi and dysplastic naevi are important phenotypic 
markers for individuals who are at risk for melanoma development, independent to their potential risk as a 
precursor lesion. It has been proposed that the increased risk of melanoma in these individuals is due to an 
inherited susceptibility to melanocyte proliferation which confers the initiating step in melanoma evolution. In 
support of this hypothesis, several studies have demonstrated a significant correlation between naevus counts in 
parents and their children, or between siblings, independent of their sun exposure patterns (Graham et al, 1999; 
Green and Swerdlow, 1989; Weicker et al, 2003), implying a genetic susceptibility to naevus development, 
independent of environmental factors. Also, distinct patterns of naevus morphology may be observed in a single 
individual, resulting in a “signature naevus”, where the majority of naevi are morphologically alike. This would 
suggest these naevi have a similar underlying genetic aberration. In agreement with this, genetic analyses of 
naevus subtypes have identified activating mutations in components of cellular transcription pathways which, in 
turn, lead to the altered expression profile of multiple transcription factors which may drive the neoplastic 
phenotype. A number of candidate genes have been proposed, including cyclin-dependent kinase inhibitor 2A 
(CDKN2A), BRAF, melanocortin-1-receptor (MC1R) and MYC (details beyond the scope of this discussion). 
Studies have further shown various exogenous oncogenes can drive melanocytes to acquire malignant and/or 
invasive characteristics in vitro (Grichnik et al, 2006). An alternative theory proposes that the increased risk of 
melanoma development in these individuals with multiple naevi may simply reflect an increased probability of 
malignancy due to a higher number of melanocytes in their skin (Green and Swerdlow, 1989).  
 
A second important finding by Tucker et al (2002) in their long-term follow up of melanoma-prone families was 
the prospective detection of 86 new melanomas in 37 individuals. Fifty-one of these melanomas were found to 
have an identified precursor lesion, based on either the presence of naevus tissue within the melanoma biopsy 
and/or the presence of a benign lesion, documented photographically, at an earlier time point. Thirty-two of 
these precursor lesions were dysplastic naevi. This study thus provides convincing evidence that, independent to 
their presence as phenotypic risk markers for melanoma, banal and dysplastic naevi also represent potential 
direct precursor lesions for melanoma development.  
 
Importantly, however, it must be noted that over one third (40.7%) of these melanomas did not arise in an 
identified precursor lesion. This is the third noteworthy finding by Tucker et al (2002). Histological and 













supported the findings of an earlier study where Kelly et al (1997) followed a cohort of 278 patients with 5 or 
more dysplastic naevi for a mean period of 42 months. Clinical examinations and serial photographs were 
recorded as described for Tucker et al (2002). This group reports the prospective detection of 20 new 
melanomas in 16 patients, with only 3 melanomas arising in a documented precursor lesion. Fifteen of the 20 
melanomas (75.0%) did not have an identified precursor lesion and were shown to arise de novo.  
 
1.6.4 An alternative route of melanoma development: the tumour stem cell hypothesis 
As previously discussed, it has long been accepted that initiating mutations could arise and drive a fully 
differentiated epidermal melanocyte along the aforementioned step-wise process of melanoma evolution. It has 
recently been proposed, however, that these mutations may actually occur in a tissue resident precursor cell and 
not in a fully differentiated melanocyte. This “initiated” progenitor cell may then be primed to respond 
abnormally to surrounding environmental signals (Grichnik, 2008; Grichnik et al, 2006; Ross et al, 2011). This 
hypothesis is known as the tumour stem cell hypothesis (further discussed in section 1.6.4.3) and is based on the 
in vitro observation of a sub-population of cells with stem-like features within tumour cultures. Stem cells have 
been identified in cultures of several malignancies including haematological (Bonnet and Dick, 1997; Wulf et al, 
2001), breast (Al-Hajj et al, 2003), brain (Kondo et al, 2004; Singh et al, 2003, 2004), pancreatic (Li et al, 
2007), colon (O’Brien et al, 2007; Ricci-Vitiani et al, 2007), lung (Ho et al, 2007) and melanoma. Evidence in 
support of the tumour stem cell model of melanoma development will be discussed below.   
 
1.6.4.1 Stem cells: a brief overview 
Stem cells are slow proliferating cells characterised by the ability to maintain their undifferentiated state through 
self renewal and to give rise to differentiated cell types (Figure 4). Embryonic stem cells are pluripotent cells 
derived from the inner cell mass of blastocyst-stage embryos. A group of “core” pluripotency transcription 
factors have been identified in both human and mouse embryonic stem cells and include OCT4, SOX2 and 
NANOG (Orkin, 2005).  
 
 
Figure 4: Stem cell biology: Stem cells are able to self renew (blue) as well as give rise to transit amplifying cells (green) 













 These transcription factors trans-activate downstream genes which in turn encode transcription factors, signal 
transduction components and chromatin modifying enzymes that promote self renewal. OCT4 (OCT3/4 or 
POU5f1) belongs to the POU transcription factor family (Nichols et al, 1998). The downregulation of OCT4 in 
both mouse and human ES cells causes cell differentiation (Niwa et al, 2000; Darr et al, 2006). SOX proteins are 
a group of transcription factors widely found in the animal kingdom. They contain a high-mobility group 
(HMG) domain and belong to the HMG box superfamily. SOX2 is essential in maintaining self-renewal of 
undifferentiated embryonic stem cells. OCT4 forms a trimeric complex with SOX2 on target regulatory 
elements to collaborate in transcriptional control of the expression of a number of genes involved in embryonic 
development. NANOG belongs to the NANOG homeobox family and binds DNA via a conserved 
homeodomain motif. NANOG has been identified as a marker for undifferentiated human ES cells and thought 
to be fundamental in maintaining pluripotency. However, its exact role in these cells is not yet fully understood. 
It is thought to interact with SMAD1, interfering with the recruitment of co-activators to the active SMAD 
transcriptional complexes and blocking bone morphogenetic protein-induced mesoderm differentiation. OCT4, 
SOX2 and NANOG co-activate a number of genes, often at apparent overlapping sites, suggesting these factors 
act in a co-ordinate manner to control the transcriptional program of pluripotency. 
 
 
                                Table 3: Definition of terms (adapted from Jaenisch and Young, 2008) 
 
1.6.4.2 Evidence for stem cells in postnatal skin 
During embryogenesis, stem cells undergo a process of selective determination, differentiation and eventual fate 
restriction as their differentiation potential, or plasticity, becomes increasingly limited (Table 3). In adult tissues, 
integrity is thought to be maintained by tissue-resident stem cells and these precursor cells have been identified 
in a wide range of human tissues, including the skin. The best described stem cell niche in postnatal skin is the 
permanent mid-portion of the hair follicle known as the bulge region which, in mice, has been shown to house 
melanocyte stem cells, giving rise to mature melanocytes in the hair bulb during normal hair cycling (Amoh et 
al, 2005; Nishimura et al, 2002; Sieber-Blum et al, 2004; Wong et al, 2006). Specific markers for these 
precursor cells have yet to be identified, but studies have shown that quiescent precursor cells in the hair follicle 













2010). This makes the detection of melanocyte precursor populations difficult. This stem cell niche has also 
been shown to give rise to epithelial stem cells (Blainpan and Fuchs, 2009) as well as neurons, glial and smooth 
muscle cells (Amoh et al, 2005), indicating either a highly plastic stem cell population, or a stem cell niche 
housing multiple stem cell lineages. Maintenance of the interfollicular epidermis was shown to involve many 
small “units of proliferation” (Blainpan and Fuchs, 2009) scattered throughout the interfollicular epidermis, 
suggesting an independent interfollicular niche of keratinocyte stem cells. To date, the presence of melanocyte 
stem cells in the interfollicular epidermis has not been definitively demonstrated, but is hypothetically possible 
and is supported by the observation of repigmentation of glabrous skin following UVA treatment in conditions 
such as vitiligo (Davids et al, 2009).  
 
A dermal reservoir for melanocyte stem cells has also been proposed, based on the theory that the dermis would 
be less exposed to physiological or chemical stress than the epidermis (Li et al, 2009). A novel population of 
dermal stem cells, termed skin derived precursors (SKP), was first described by Toma (2001) where dissociated 
mouse dermis was shown to be capable of generating free-floating spheres, resembling neurospheres. Further 
studies have demonstrated a neural crest origin of SKPs and have been shown to be capable of differentiating 
along glial, neuronal, mesenchymal and melanocytic lineages (Fernandes et al, 2004, 2008; Wong et al, 2006). 
Li et al (2009) isolated a similar multipotent dermal precursor from human foreskin, termed dermal stem cells 
(DSC), which expressed additional embryonic stem cell markers OCT4 and NESTIN, not previously shown in 
SKPs. This group further demonstrated, via a three-dimensional skin equivalent model, the sphere forming 
dermal stem cells migrated from the epidermis to the dermis, differentiating into mature HMB45-positive 
melanocytes. This study demonstrated, for the first time, the existence of a dermal reservoir of melanocyte stem 
cells. A defined, spatially restricted niche for these melanocyte precursors has not yet been reported. 
 
Belicchi et al (2004) described a population of pluripotent cells in human skin which expressed the neural crest 
stem cell marker CD133 and differentiated into neurons, astrocytes and glial cells. CD133 has also been 
identified in endothelial cells and mast cell precursors. Interestingly, mast cells have been shown to insert into 
the hair follicle following bone marrow transplantation and Grichnik (2008) has proposed it may be possible that 
both mast cells and melanocytes are derived from a circulating CD133+ precursor, and further, that this may be 
the mechanism resulting in spontaneous repigmentation of grey hair. Whether this may also be used to explain 
eruptive naevi, circulating naevus cells or the observation of naevus cells in lymphoid tissues remains uncertain.  
 
1.6.4.3 The tumour stem cell hypothesis in the evolution of melanocytic naevi and melanoma 
As discussed above, the in vitro observation of a sub-population of cells with stem-like features within tumour 
cultures has led to the hypothesis known as the tumour or cancer stem cell hypothesis. The identification of stem 
cell niches and cells of a precursor phenotype which persist in post-natal tissues has made this hypothesis 













which has undergone a mutational event and not from a fully differentiated cell as previously accepted. It is 
hypothesised that this mutated precursor cell responds abnormally to local environmental signals and, when 
recruited, may result in a genomically unstable transit amplifying population (refer to Figure 4) which forms the 
bulk of the tumour. These cells may then initiate differentiation and, depending on the nature of the underlying 
mutation, or on the presence of cumulative mutations, varying degrees of differentiation may be reached. Self-
limiting defects may allow the cells to retain normal cellular functions and responses to local environmental 
signals, resulting in a neoplasm more similar to normal tissue and hence growing in a benign manner, while 
more severe defects, or cumulative defects, may result in autonomy of surrounding signals, a limitless 
replicative potential, the ability to invade local tissues and/or metastasise and hence, malignancy. Of importance, 
this model suggests that only a subpopulation of self-renewing tumour cells drive tumour formation. This is in 
contrast with the stochastic model of tumour development, which advocates that all cells within a tumour are 
capable of tumour generation. In addition, the resultant transit amplifying population may carry varying 
numbers of mutations and/or reach varying degrees of differentiation, both of which may result in a 
heterogeneous population of cells within a single tumour mass, a well described finding in tumour biopsies and 
cultures (discussed in 1.6.4.4 below).  
 
This tumour stem cell hypothesis provides an attractive model of tumour development in general. It can be used 
to explain tumour dormancy, as precursor cells would exist unstimulated for long periods of time before being 
recruited and giving rise to mutated progeny. It can simplify the concept of “de-differentiation”, the process 
whereby a cancer cell is said to progress from a cell resembling a fully differentiated cell, to one resembling a 
precursor phenotype (i.e. a reversed process of differentiation), a process which has not be fully explained to 
date. It is well accepted that cells resembling their differentiated counterparts tend to behave in a more benign 
manner, while those losing this phenotype, known as “un-differentiated” or anaplastic cells, tend to behave in a 
far more malignant manner and carry a worse prognosis. For this reason, “un-differentiated” cells were thought 
to represent a later stage in cancer development. However, this process of “de-differentiation”, and why a cell 
would revert to a precursor phenotype, has not been adequately described. The tumour stem cell hypothesis can 
also be used to explain metastases. Here, metastases can be explained by stem cell biology alone, including 
smaller size and differences in adherence. It is further been proposed that these highly migratory embryonic 
cells retain their ability to migrate and, if these tumour stem cells circulate, they may give rise to distant 
metastases. Lastly, the tumour stem cell hypothesis may explain the poor regression rates observed in certain 
malignancies. It is proposed that rapidly dividing and differentiated cells are destroyed by chemotherapeutic 
strategies and the immune system response, while the slow-dividing stem-like cells, which feed the malignancy, 
may be overlooked (Grichnik et al, 2006). This may also be used to explain late local recurrence or metastasis 














The tumour stem cell model also proves an attractive hypothesis in naevus and melanoma development 
specifically. Firstly, it can be used to explain the multiple subtypes of lesions observed. Melanocytic neoplasms 
demonstrate numerous different, yet repeatable, patterns both clinically and histologically which allows for 
classification of these neoplasms into specific subtypes. They display variations in colour, size, morphology and 
distribution, yet show reproducible patterns within each specific subtype. It has been proposed that each distinct 
pattern represents a distinct underlying mutation, developmental phase or local signalling environment 
(Grichnik, 2008) (Figure 5). Similarly, precursor cells higher in the dermis and epidermis would be exposed to 
normal epidermal environmental cues and develop along melanocytic lines, while those deeper in the dermis 
would be removed from epidermal stimuli and/or exposed to altered stimuli in the dermal environment and may 




Figure 5: Theoretical growth patterns of melanocytic neoplasms: A mutated dermal precursor cell (brown) attempting 
normal developmental pathways to the epidermis. Varying clinical and histological subtypes would result depending on the 
mutation and/or local environmental influences (Grichnik, 2008). 
 
The tumour stem cell model, however, is based on a static cross-sectional analysis of neoplastic tissues and the 
temporal development of these neoplasms cannot be accurately concluded. It is entirely possible that these 
precursor-like cells result from differentiated cells which have undergone a mutational event, reverting to a 
stem-like phenotype. Thus, the “cancer stem cell hypothesis” does not imply that the “cell of origin” is a true 














1.6.4.4 Evidence for the tumour stem cell model in melanocytic naevi and melanoma 
In considering the tumour stem cell model in melanoma development, a number of studies have shown data in 
support of this hypothesis. Melanomas have been shown to exhibit phenotypic heterogeneity, both in vivo and in 
vitro, suggesting an origin from a cell with multi-lineage differentiating abilities. Fang et al (2005) report a sub-
population of melanoma cells which propagate as non-adherent spheres and individual cells which are able to 
differentiate into multiple cell types, including melanocytes, adipocytes, osteocytes and chondrocytes, imitating 
the plasticity of neural crest stem cells. Grichnik et al (2006) studied melanoma cell lines and their ability to 
efflux Hoechst 33342 dye, a technique known to enrich for stem cells in many tissues, to separate cell 
populations. The cells with the greatest ability to efflux the dye were small in size, less melanised and gave rise 
to larger cell forms. They exhibited lower proliferative rates, but had the greatest ability to expand in culture. 
These findings are in keeping with stem cell biology. Neural crest stem cell markers CD133, nestin (Klein et al, 
2007) and HNK1 (Thies et al, 2004) have been described in cutaneous melanoma cultures suggesting the 
presence of a neural crest precursor phenotype. Schatton and Frank (2008) showed a subset of cells in primary 
and metastatic melanoma express the neural crest stem cell marker p75 (CD271). These cells displayed a 
markedly enhanced capacity for self renewal, increased differentiation plasticity and the ability to form tumours 
and metastasize when injected into mouse models, as compared to p75 negative cells from the same melanomas.  
 
What the above studies interestingly indicate is that not all melanoma cells are equally tumorigenic. Instead, 
subsets of tumour cells appear to exist which are capable of increased self-renewal and differentiation plasticity. 
In opposition to the above, Quintana et al (2008) showed efficient tumour formation from single, unsegregated 
melanoma cells. In a subsequent study, Quintana et al (2010) showed a high proportion of melanoma cells to be 
tumorigenic (28%) and no specific marker could distinguished tumorigenic from non-tumorigenic melanoma 
cells. In addition, surface markers appeared to be reversibly expressed by tumorigenic melanoma cells. It has 
been suggested that the disparity regarding cancer stem cells may result from variations in the methodology used 
to study such cells, and that the tumour microenvironment and host immune system response may affect the 
frequency and phenotype of melanoma stem cells (as reviewed by Girouard and Murphy 2011; Gupta et al, 2009 
and Kennedy et al, 2007). 
 
1.7 Study rationale, aims and specific objectives  
In considering all the above, including evidence for the existence of stem-like cells in melanoma cultures, the 
disparity with regards to specific cancer stem cell markers and the role of microenvironmental influence on cell 
phenotype, one cannot exclude the impact of in vitro conditions on cell morphology, phenotype and selective 
outgrowth. To our knowledge, no data exists for the in vivo identification and/or characterisation of precursor 
cells within naevus or melanoma biopsies. This study has therefore selected to analyse human biopsy samples 
by direct immunofluorescence in order to determine the in vivo presence, or absence, of precursor cells. 













naevus (Kincannon and Boutzale, 1999), are easy to detect clinically, and are commonly removed for cosmetic 
and/or diagnostic purposes thus being widely available for histological examination, naevi have received very 
little attention in current literature. Also, the occurrence of “de-differentiated” cells in some melanomas, and the 
current lack of understanding as to the overlap between “de-differentiated” and precursor or stem-like cells in 
general, may cloud the issue should precursor cells be found within melanoma tissue. As a result, in this study it 
is proposed that the benign melanocytic naevus is an underutilised and model system with which to study 
tumour stem cell biology. Melanocytic naevi may well provide critical information on the role of stem cells 
and/or melanocytes as a possible initiating event in both benign and malignant disorders. This knowledge may 
thus assist in advancing the understanding of such disorders and facilitate refining of classification, diagnosis 
and treatment strategies.   
 
1.7.1 Broad aims 
The broad aims of this study are to provide a detailed phenotypic characterisation of a naevus cell, and to 
examine the hypothesis that melanocytic naevi may originate from a pluripotent or neural crest-like stem cell 
and not via de-differentiation from a mature epidermal melanocyte. 
 
1.7.2 Objectives 
 To determine the in situ expression and distribution of key melanocyte markers in acquired melanocytic 
naevi and to establish whether these markers are typical of mature epidermal melanocytes or of a 
precursor phenotype. 
 To determine the in situ expression and distribution of key Schwann cell markers in acquired 
melanocytic naevi and to establish whether these markers are typical of mature myelinating Schwann 
cells or of a precursor phenotype. 
 To determine the in situ expression and distribution of neural crest markers in acquired melanocytic 
naevi.  
 To determine the in situ expression and distribution of stem cell markers in acquired melanocytic naevi.   
 To establish whether the five selected subtypes of acquired melanocytic naevi (junctional, compound, 
intradermal, dysplastic and blue naevi) are similar or different with regards to cellular composition and 
distribution of precursor cells, if present. And to examine whether the presence of precursor cells is 
related to an increased risk of malignant transformation, as determined by “high-risk” dysplastic 
subtypes. 
 To determine, if present, the proliferating compartment of naevi; and thus identify a potential 
compartment of origin of melanocytic neoplasms and/or a potential niche for melanocyte stem cells 














1.7.3 Approach and selection of markers  
Melanocytic naevi have been shown to display features of both melanocyte and Schwann cell lineage. The cell 
of origin, and subsequent pathogenesis, of a “naevus” cell thus remains to be fully understood. In order to fully 
characterise a naevus cell phenotypically, markers of melanocyte and Schwann cell lineage were selected. 
Melan-A (MART-1) is a melanocyte differentiation antigen which is specific to melanocytes of normal skin, 
melanomas and retinal pigment epithelium, but is not expressed in other tissues. Antibodies against this antigen 
are widely used in anatomical pathology in order to detect cells of melanocyte lineage as it is a highly sensitive 
and specific marker (Sheffield et al, 2002; Snyder and Paulino, 2002). S100 is a large family of calcium channel 
binding proteins. In the skin, S100 is expressed in melanocytes, Langerhan’s cells and dermal dendritic cells. It 
is considered the most sensitive marker for differentiated melanocytes, yet its lack of specificity limits its use as 
a single diagnostic marker (Sheffield et al, 2002; Snyder and Paulino, 2002).  
 
As discussed previously, p75 is expressed in NCC prior to commitment to either melanoblast or Schwann cell 
fate. P75 continues to be expressed in myelinating Schwann cells where it would be expected to be co-expressed 
with S100. It is not expressed in normal skin melanocytes, and thus a p75 positive but S100 negative 
(p75+/S100-) cell, not in association with dermal nerves, would suggest a cell of neural crest phenotype. OCT4 
and NANOG are transcription factors important in maintaining pluripotency of embryonic stem cells. They are 
highly expressed in undifferentiated embryonic stem cells and expression decreases gradually after embryoid 
body formation. Both markers have been identified in certain malignant tissues of embryonic origin, as well as 
foetal gonads, ovary and testis. Tai et al (2005) examined human normal tissue arrays for the expression of 
OCT4. One weakly OCT4-positive cell was unconvincingly demonstrated in the basal layer of the epidermis and 
thought to represent an epidermal stem cell. At present, there is no convincing data for the demonstration of 
OCT4 and/or NANOG positive cells in normal human skin.  
 
Ki-67 is a proliferation marker expressed throughout all stages of the cell cycle except G0, when it cannot be 
detected. It localises to the nucleus where it is predominantly located in the perinucleolar region in the G1 phase, 
and in the later phases, provides a more diffuse pattern by dispersing throughout the nuclear matrix.  It was thus 




















2. Materials and Methods 
2.1 Tissue culture 
Positive “tissue” controls for OCT4 and NANOG immunostaining were generated from cultured mouse 
embryonic stem (mES) cells and human induced pluripotent stem cells (iPS) respectively. All tissue culture was 
carried out in a Bio-Flow Biological Safety Cabinet Class II. All surfaces, microscopes, bottles, tubes, gloves 
and instruments were sterilised by wiping with a 70% ethanol solution immediately prior to working with them. 
Gloves were worn at all times. Cells were incubated in a Forma Scientific water-jacketed incubator (Thermo 
Scientific, USA) at 37
o
C, 5% CO2. 
 
2.1.1  Culture of mouse embryonic fibroblasts (MEF) feeder layers 
Mouse embryonic fibroblasts (MEFs) from 14 day old mouse embryos were harvested according to standard 
procedures by Robea Ballo (Evans and Kaufman, 1981; Martin, 1981). All cells used were at passage 2 and 
were cultured in MEF medium consisting of Dulbecco’s modified Eagles medium (DMEM) (Highveld 
Biological, South Africa) supplemented with 10% foetal bovine serum (FBS) (Gibco, USA), 100 U/ml penicillin 
(Sigma-Aldrich, USA), 100 µg/ml streptomycin (Sigma-Aldrich, USA), 1% non-essential amino acids (Gibco, 
USA) and 0.1 mM β-mercaptoethanol (Merck, Germany). Cells were cultured in 10 cm dishes (Corning Inc., 
USA) and medium was changed every 3-5 days depending on cell density. Cells were passaged when reaching 
90% confluence using a 0.05% trypsin/EDTA (TE) solution, were split 1:3 and seeded into 10 cm plates. MEFs 
were not used beyond passage 5.  
 
2.1.2 Mitotic inactivation of MEFs 
Mitomycin C inhibits cell division by cross-linking DNA and is widely used as a chemotherapeutic agent by 
virtue of its antitumour and antibiotic activity. In cell culture systems it is used for mitotic inactivation, 
inhibiting cell division, yet allowing continued cell metabolism. MEFs at passage 3-4 were inactivated using 
mitomycin C (Sigma-Aldrich, USA). Briefly, MEF medium was removed from plates and cells were washed in 
1x PBS. Cells were then incubated in MEF medium containing 10 µg/ml of mitomycin C for 3 hours at 37°C. 
Following inactivation cells were thoroughly washed in 1x PBS to remove all traces of mitomycin C, trypsinised 
and resuspended in MEF medium. Cells were subjected to repeat trituration in order to generate a single cell 
suspension and counted using a haemocytometer (Marienfeld, Germany). Cells were seeded in a 6 well plate at a 
density of 5 x 10
5
 cells/well in MEF medium, in preparation for use with mouse embryonic stem (mES) cell 
cultures. Inactivated MEFs (iMEFs) were seeded a minimum of 24 hours prior to mES cell seeding in order to 
allow for adequate formation of a feeder layer. Inactivated MEFs were used for a total of 7 days following 















2.1.3 Mouse embryonic stem cell (mES cell) culture 
Mouse ES cells (stocks prepared by Allison Patterson in the Kidson laboratory) were thawed and seeded in 35 
mm dishes containing a feeder layer of iMEFs. Cells were grown in mES cell medium containing DMEM 
(Highveld Biological, South Africa) supplemented with 15% FBS (Gibco, USA), 100 U/ml penicillin (Sigma-
Aldrich, USA), 100 µg/ml streptomycin (sigma-Aldrich, USA), 1% non-essential amino acids (Gibco, USA), 
0.1 mM β-mercaptoethanol (Merck, Germany) and 1% Leukaemia inhibitory factor (LIF) (courtesy of the 
Department of Immunology, UCT). LIF is a cytokine which has been isolated from the conditioned medium of 
certain feeder layers and is important in suppressing mES cell differentiation by its interaction with the 
transcription factor STAT3 (Matsuda et al, 1999). In this study, LIF was acquired from the conditioned medium 
of the CHO-cell line and diluted 1:400 in PBS to result in a working stock solution. Medium was changed every 
1-3 days depending on colony density. 
 
Mouse ES cells were expanded every 2-4 days according to colony density, size and morphology (as 
recommended by Robertson, 1987). Colonies were lifted using 300 µl of dispase (5 mg/ml) (Sigma-Aldrich, 
USA) per 35 mm dish as it was found to selectively lift mES cell colonies before disrupting the underlying 
feeder layer. A single cell suspension was generated by repeat trituration before sub-culturing. From each 35 
mm dish one third was seeded on an existing feeder layer of iMEFs to expand the mES cultures and 
subsequently passaged as above. The remaining two thirds were either: (i) placed in a 10 cm dish on an existing 
feeder layer of inactivated PA6 cells for neurosphere generation (section 2.1.7), (ii) one third placed in 500 µl 
Tripure (Roche Diagnostics, USA) for RNA extraction (not detailed here), and one third frozen down to restore 
stocks, or (iii) two thirds embedded in HistoGel
TM
 (Richard-Allan Scientific, USA) for immunofluorescence 
(section 2.2.3.2[b]). 
 
2.1.4 PA6 cell culture 
PA6 cells are derived from newborn mouse calvaria (Kodama et al, 1982). Cells were grown in PA6 medium, 
consisting of DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. The PA6 
cell line used in this study showed a loss of contact inhibition and cells were inactivated using mitomycin C 
according to the above protocol (section 2.1.2, PA6 medium was substituted for MEF medium). Although this 
technique has been described (Schwartz CM et al, 2005) it had not been used previously in our laboratory. 
Mitomycin C inactivation of PA6 cells was verified by a growth curve (section 2.1.5).  
 
2.1.5 Verification of mitomycin C inactivation of PA6 cells 
A defined number of inactivated PA6 (iPA6) cells (2 x 10
5
) were seeded onto numerous 35 mm plates and 
cultured in PA6 medium (section 2.1.4) for growth rate analysis. Cells were counted on either day 2, 3, 6 or 9 













and showed a slight drop off in cell number and importantly, no increase in cell number, thus validating the 
inactivation of PA6 cells by mitomycin C.  
 
2.1.6 Determining the seeding density of iPA6 cells 
Since PA6 cells have not been routinely inactivated, the concentration of iPA6 cells required to generate a stable 
80-90% confluent feeder layer needed to be determined. Here, iPA6 cells were seeded onto numerous 35 mm 
dishes in the following concentrations (i) 1 x 10
5
, (ii) 2 x 10
5
, (iii) 3 x 10
5
, (iv) 4 x 10
5
 and (v) 5 x 10
5 
and 
cultured in PA6 medium
 
(section 2.1.4). Cells were visualised over the next 7 days and an optimal seeding 
density of between 2 x 10
5 
and 3 x 10
5
 was noted to result in an 80-90% confluent feeder layer. For the 
remaining iPA6 work, a seeding density of 2.5 x 10
5
 per 35 mm dish was used, and was adjusted proportionately 
for 6 cm and 10 cm plates.  
 
2.1.7 Generation of neurospheres from mES cells 
Inactivated PA6 cells were seeded at the above density onto 10 cm plates and allowed to recover overnight in 
PA6 medium (section 2.1.4). Sub-cultured mES cells were seeded on the iPA6 feeder layers and grown in 
DMEM supplemented with 1% FBS, 10% Knock Out Serum Replacement (Gibco, USA), 100 U/ml penicillin 
and 100 µg/ml streptomycin. At 10-14 days following seeding of mES cells, colonies had started to lift and 
formed neurospheres in suspension as described by Kitajima et al (2005). Medium containing neurospheres was 
removed using a wide-bore pipette and gently centrifuged. The resultant neurosphere pellet was resuspended by 
gentle trituration, taking care not to fracture the neurospheres, and whole neurospheres were transferred to the 
inverted lid of a 6cm dish (TPP, Europe) which was contained within a 10cm dish (Corning Inc., USA). Medium 
was replaced every 3-4 days by removing 4-5ml of medium from the edge of the dish, taking care not to remove 
any neurospheres. Fresh medium was then added.  
 
Neurospheres propagated by “budding off” (refer Results, Figure 18) and dishes were sub-cultured by removing 
medium containing neurospheres in a wide-bored pipette and placing in a new 6 cm dish. After a further 14 days 
of propagation, neurospheres were either (i) embedded in HistoGel
TM
 for immunofluorescence analysis (section 
2.2.3.2 [b]), (ii) frozen down for stock (section 2.1.8) or (iii) resuspended, after careful trituration, in 1 ml 
Tripure (Roche Diagnostics, Germany) for RNA extraction (not detailed here).  
 
2.1.8 Freezing down of cells 
Neurospheres, MEFs, iMEFs, PA6s and iPA6s were frozen down for storage and later use. This ensured 
adequate stocks for future research, as well as a constant availability of inactivated feeder layers for immediate 
use when required. Briefly, cells were washed in 1x PBS and lifted with TE. The resultant cell suspension was 













(Merck, Germany). This was then placed in cryogenic tubes (Greiner bio-one, Germany), cooled slowly 
overnight in a cotton wool lined box at -80°C and transferred to liquid nitrogen storage the following day. 
 
2.1.9 Mycoplasma analysis and treatment 
Mycoplasma, an intracellular bacterium, is a common contaminant in cell culture and may induce cellular 
changes, including chromosome aberrations, changes in cellular metabolism and cell growth. Cultured cells 
were thus tested routinely for mycoplasma infection using a Hoechst (Sigma-Aldrich, USA) nuclear stain and 
standard operating procedure as outlined by Chen (1977). Cells were viewed under the appropriate channel 
using a Zeiss Axiovert 200M microscope and images were captured using the Zeiss Axiocam HR monochrome 
camera. Cells infected with mycoplasma were treated with 10 µg/ml Ciprobay (Highveld Biological, South 
Africa) every 12 hours in fresh medium for 3 days and then re-stained with Hoechst as above. No cell line 
testing positive for mycoplasma was used in this study. 
 
2.1.10 Microscopy of cultured cells 
Cells were periodically photographed for record purposes. Cells were visualized using an Olympus CKX41 
Microscope (Olympus, Japan) and photographed using a Canon Powershot S50 (Canon, Japan). 
 
2.1.11 Human induced pluripotent stem cell (iPS) culture 
Samples for optimisation of immunofluorescence protocol for pluripotency marker NANOG used human 
induced pluripotent stem cells (iPS) which were kindly donated by Lauren Watson and Danielle Smith, Human 
Genetics, University of Cape Town.  
 
2.2 Immunofluorescence 
2.2.1 Study samples 
Biopsy samples of melanocytic naevi from human skin were obtained from the archives of the National Health 
Laboratory Services (NHLS), courtesy of Professor D. Govender, NHLS, Groote Schuur Hospital (GSH). These 
samples were previously obtained from patients who had undergone a biopsy of a pigmented lesion, which was 
subsequently histologically confirmed as a benign melanocytic naevus and archived in the NHLS archives. All 
samples were formalin-fixed and paraffin-embedded at the time of biopsy. Each sample was given a 
histopathological diagnosis of a benign melanocytic naevus by a qualified anatomical pathologist. A total of ten 
samples were included in this study. Five subtypes of acquired melanocytic naevi (two samples within each 
subtype) were included: junctional, compound, intradermal, dysplastic and blue naevi. 
 
Study samples were kindly sectioned by Heather McLeod, Department of Anatomical Pathology, GSH, as 
described in section 2.2.3.1(b). A total of 15 sections were obtained from each naevus sample, generating one 













2.2.2 Patient clinical information 
Patient folders were made accessible in order to access relevant clinical information. Details regarding age, sex, 
anatomical site, change in appearance, personal or family history of melanoma and subsequent re-presentation 
for naevus/melanoma biopsy were noted for correlation with immunofluorescence findings (refer Results, Table 
6). Full ethical approval to access patient folders was obtained from the Human Research Ethics Committee, 
UCT, (HREC:REF 553/2010) as well as provincially from the Western Cape Department of Health (RP 
159/2011) (Appendix B). 
 
2.2.3 Control samples  
Naevus biopsy samples were formalin-fixed and paraffin embedded (FFPE) at time of initial biopsy and IF 
protocols were thus optimised for FFPE tissues. Positive controls for Melan-A (epidermal melanocytes), S100 
(epidermal Langerhan’s cells), Ki-67 (suprabasal keratinocytes) and p75 (epineurium and perineurium of dermal 
nerves) are found in normal skin and therefore control skin biopsies were used to optimise the IF protocol for 
these antibodies in FFPE tissues. Positive controls for OCT4 and NANOG are not reliably present in normal 
human skin and optimisation of these antibodies was performed using cultured mES and iPS cells respectively 
(discussed in section 2.2.3.2 below). Optimised protocols for antibodies in FFPE tissues are detailed in Table 4. 
 
2.2.3.1 Control skin biopsies 
Human skin biopsies were obtained from the Department of Plastic Surgery, Groote Schuur Hospital. These 
samples consisted of excess tissue which was donated following a scheduled surgical procedure. Informed 
consent was obtained prior to the procedure in all cases. Samples used in this study were obtained from 
reduction mammoplasties of middle aged females, of both African and Caucasian skin types. Specimens were 
placed in sterile specimen bags and transported directly to the Department of Human Biology laboratory on ice. 
All subsequent work was performed in a Bio-Flow Biological Safety Cabinet Class II and gloves were worn at 
all times. A 2 mm punch biopsy was made and this was placed in the lid of a 10 cm dish and washed in PBS to 
remove all traces of blood. This was then transferred to a 15 ml centrifuge tube (TPP, Germany) and fixed in 10 
ml of 4% formaldehyde for 30 minutes.  
 
2.2.3.1 (a) Paraffin embedding of control samples 
Following fixation in 4% formaldehyde in PBS, skin biopsy samples were placed in tissue cassettes and 
processed according to a standard protocol for tissue processing (Boenisch et al, 2001) Briefly, samples were 
placed in an automatic tissue processor (Shandon Scientific, England) for overnight processing where they were 
dehydrated through a series of increasing grades of ethanol and then cleared in xylol prior to wax impregnation. 
The following day, samples were embedded in a wax “tissue block” (Kunz Instruments, Denmark) in 














2.2.3.1 (b) Sectioning of control samples 
Tissue blocks were sectioned at 4 µm using a microtome (Reichert-Jung, RSA). Sections were mounted on 
Thermoscientific Superfrost Plus slides (Menzel-Glaser, Germany). These slides were utilised to ensure 
adequate adherence of the section to the slide during subsequent antigen retrieval steps. Sections were then 
placed at 60°C overnight and transferred to 37°C for a further 3 hours. Sections were stored in air-tight slide 
boxes at 4°C to prevent excessive drying prior to staining.  
 
2.2.3.2 Control samples generated from cultured cells 
2.2.3.2 (a) Immunocytochemistry (ICC) 
Positive expression of selected markers in cultured cells was first confirmed by ICC. Cells grown on a coverslip 
in a 35 mm plate were washed in 1x PBS and fixed in 4% formaldehyde (Merck, Germany) in PBS for 30 
minutes, then washed three times in 1x PBS, 10 minutes each. Cells were blocked for one hour at room 
temperature in 500 µl of blocking solution, containing 1x PBS, 5% FBS and 0.01% Triton X (BDH Chemicals 
Ltd, RSA). The block was aspirated and samples incubated with 300 µl primary antibodies at 4
o
C overnight in a 
humidified chamber. Primary antibodies were diluted in 1% FBS in 1x PBS according to manufacturers 
recommendations, and further optimised by serial dilution if required. Primary antibodies and their dilutions 
were identical to those used for immunofluorescence analysis and are outlined in Table 4. The following day, 
cells were rinsed three times in 1x PBS, 5 minutes each, and incubated for 1 hour at room temperature in the 
dark with secondary antibodies (Jackson ImmunoResearch, USA), where antibodies and dilutions were also 
identical to those used for immunofluorescence analysis and outlined in Table 4. Cells were rinsed as above and 
mounted using mowiol and viewed under the appropriate channel using a Zeiss Axiovert 200M microscope and 
images were captured using the Zeiss Axiocam HR monochrome camera.  
 
2.2.3.2 (b) Formalin-fixation and paraffin-embedding of cultured cells  
Cultured mES cells and neurospheres were used to optimise the IF protocol for OCT4 and p75 in FFPE samples 
respectively. Unfortunately human iPS could not be generated in sufficient quantity to allow for FFPE of these 
cells and NANOG was optimised in cultured cells only.  
 
Cultured mES cells and neurospheres (section 2.1.3 and 2.1.7 respectively) were subject to gentle trituration to 
generate a single cell suspension. Cells were washed three times in 1x PBS and fixed in 4% formaldehyde in 





 is a specimen processing gel which encapsulates small, friable and cytological 
specimens, while not interfering with staining processes. HistoGel
TM
, which is solid at room temperature, was 
heated in a microwave oven for 30 seconds, or until liquid, and 500 µl of heated solution was added to the cell 
pellet using a wide-bore pipette. The cell pellet was gently resuspended in the liquid and transferred via a wide-













the Eppendorf tube upside down on its closed lid. This resulted in the contents settling in the lid of the inverted 
tube and allowed for easy removal of the HistoGel
TM
 pellet once solidified. The tube was cooled on ice to allow 
the HistoGel
TM
 to solidify. The HistoGel
TM
 -pellet was then carefully removed by opening the lid. The resultant 
cylindrical HistoGel
TM
 -pellet was dislodged from the lid using tissue forceps and placed in filter paper and into 
a tissue cassette for further processing, wax impregnation and tissue sectioning as described in section 2.2.3.1 
above.   
 
2.2.4 Optimisation of immunofluorescence protocol in FFPE control tissues 
2.2.4.1 Antigen retrieval: 
It is well recognized that formaldehyde fixation of tissues induces artefact by cross-linking of protein amino acid 
residues which may lead to masking of tissue antigens. Many antigen retrieval techniques have been devised to 
unmask these hidden antigen epitopes and recover immunoreactivity. Methods include (i) enzymatic digestion, 
known as proteolytic induced epitope retrieval (PIER) and (ii) heating of tissues by various methods, known as 
heat induced epitope retrieval (HIER). Methods include the use of a water bath, pressure cooker or microwave 
oven.  
 
In this study, all antibodies were optimised for HIER using a pressure cooker. Melan-A, Ki-67, S100, p75 and 
NANOG were optimised using a 10mM Citrate buffer (pH 6.0). Briefly, slides were placed in a plastic Coplin 
jar, containing 50 ml Citrate buffer solution. A maximum of 4 slides per Coplin jar was used to allow for 
adequate buffer-to-slide ratio. This was then placed in a pre-heated pressure cooker for 20 minutes. Following 
this, the samples were removed from the pressure cooker and allowed to cool within the buffer for a further 20 
minutes to allow for re-forming of antigenic sites. OCT4 was optimised using a 1 mM EDTA buffer (pH 8.0) 
and similarly heated in a pressure cooker for 5 minutes, followed by a 5 minute cooling period. 
 
2.2.4.2 Blocking solution 
The blocking solution consisted of a 1% Bovine Serum Albumin (BSA) (Roche Diagnostics, USA) in 1x PBS. 
All samples were blocked for 1 hour at room temperature in a humidified incubation chamber. 
 
2.2.4.3 Primary and secondary antibody dilutions 
For all samples, primary and secondary antibodies were diluted in 1% BSA in 1x PBS. Primary antibodies were 
incubated overnight at 4°C in a humidified incubation chamber. Secondary antibodies were incubated for 2 
hours at room temperature in a humidified incubation chamber in the dark. Optimised protocols for antibodies 














Table 4: Optimised immunofluorescence protocols in FFPE samples. Primary and secondary antibodies, and their 
respective dilutions, were identical for immunocytochemistry (ICC) analysis but no antigen retrieval step was required. 
 
2.2.5 Immunofluorescence of naevus study samples 
Slides were place on a heating block (Kunz Instruments, Denmark) for 15 minutes or until wax thoroughly 
melted. Slides were then cleared in xylol and rehydrated through a series of alcohols to tap water as according to 
standardized protocols (full protocol, Appendix c). Heat induced epitope retrieval (HIER), using a pressure 
cooker, was utilised to unmask antigenic sites (section 2.2.4.1). Samples were washed three times in phosphate 
buffered saline (PBS) and placed in a humidified incubation chamber, blocked with 1% BSA for 2 hours and 
incubated with primary antibodies overnight at 4
o
C as detailed in Table 4. The following day, samples were 
rinsed three times in PBS and incubated with secondary fluorescent-conjugated antibodies for 1 hour at room 
temperature in a humidified incubation chamber in the dark. Secondary antibodies were diluted in 1% BSA at 













1x PBS in the dark and mounted with mowiol. Sections were allowed to dry for 1 hour at room temperature in 
the dark and then placed at 4°C until viewing using the Zeiss microscope as detailed below (section 2.2.9). 
 
2.2.6 Dual labelling 
A double-staining or dual labelling IF protocol was developed which was identical for all steps outlined in 
section 2.2.5 above. Samples were incubated with a cocktail of primary antibodies, including Melan-A and Ki-
67 (1:25 and 1:200 respectively) and Melan-A and S100 (1:25 and 1:100 respectively); and the correct final 
concentrations for each antibody was ensured. For the secondary incubation step, a similar cocktail of secondary 
antibodies - donkey anti-mouse Cy3 and donkey anti-rabbit Alexa (1:1000 and 1:500 respectively) was applied 
and subsequent steps as per section 2.2.5 above.   
 
2.2.7 Internal and external controls in naevus sample analysis 
Positive and negative controls were included in each section analysed, as outlined in Table 5. These controls 
were used to ensure optimal staining procedures in every section analysed regardless of day or time of IF 
processing. An autofluorescent control was performed to detect the tissues normal autofluourescence and 
“fixative-induced” fluorescence as a result of the above fixation, processing, antigen retrieval and blocking 
steps. Once the IF protocol for each antibody had been determined, optimised and verified, the external and 
autofluorescence controls were omitted. These were, however, performed periodically throughout the study to 
ensure ongoing adequate technique. No change in technique for any of the antibodies was required.  
 













2.2.8 DAPI staining 
DAPI (4',6-diamidino-2-phenylindole), is a fluorescent stain that binds strongly to A-T rich regions in DNA. It 
is thus an important nuclear stain and is used extensively in fluorescence microscopy. In this study, DAPI was 
utilised to verify the nuclear positioning of OCT4 and NANOG staining. Following incubation of secondary 
antibodies and subsequent washes samples for OCT4 and NANOG were incubated with DAPI (Sigma-Aldrich, 
USA) (1:50, diluted in 1% BSA in 1x PBS) for 20 minutes in a humidified incubation chamber in the dark. 
Following incubation, samples were washed 3 times in 1x PBS and mounted as per section 2.2.5 above.  
 
2.2.9 Viewing and image capturing 
Slides were viewed under the appropriate channel using a Zeiss Axiovert 200M microscope and images were 
captured using the Zeiss Axiocam HR monochrome camera and Zeiss Axiovision 4.8 software program. For 
each run of each sample, the exposure time was optimised and subsequently set so that intensity of staining 
could be compared throughout the sample. This was not able to be standardised across samples due to differing 
staining intensity on different days, so intensity of staining is not comparable across samples.  
 
2.2.10 Haematoxylin and Eosin stain (H&E)  
All naevus samples were sectioned and numbered section 1-15. The middle section of each biopsy series, 
section 8, was subject to standard protocol for H&E staining and the other sections subject to IF analysis 
detailed above. Each H&E section was viewed using a Zeiss AxioSkop M microscope and images were captured 
using the Zeiss Axiocam HRc camera and Zeiss Axiovision 4.7 software program. The distribution of naevus 
cells recorded using a Zeiss Axiocam HR monochrome camera. Fluorescent images were correlated with 
corresponding H&E images to ensure data analysis was performed on representative areas of naevus cells only.  
 
2.3 Analysis 
2.3.1 Qualitative analysis 
Ten naevus samples (two samples within each of five different subtypes) were included in the analysis and the 
expression of six antigens examined by IF. For each antigen, at least two sections were analysed, a minimum of 
ten sections apart (Figure 6a). In cases where large biopsies were divided into two or three fragments prior to 
fixation and wax impregnation, a total of four to six sections were analysed (Figure 6b). Qualitative analysis was 
performed by examining the entire immunolabelled section and noting the overall characteristics of IF staining, 
including the distribution, morphology and intensity of staining. Dual labelling techniques and serial section 















Figure 6: Diagrammatic representation of tissue sections generated from naevus biopsy samples. 
 
2.3.2 Quantitative analysis 
Quantitative analysis was performed by determining the proportion of positively labelled naevus cells per total 
naevus cells counted. For each biopsy sample, two sections (a minimum of ten sections apart) were subject to 
analysis with one of the six selected antibodies. Ten high power fields (HPF) evenly distributed throughout the 
bulk of the naevus biopsy which contained areas representative of naevus tissue were evaluated per sample, 
giving a total of twenty HPFs analysed for each antibody in each section. To determine the relationship between 
naevus occurrence and epidermal keratinocyte proliferation, the ten naevus samples and ten control skin samples 
were analysed. Five HPF were selected in each of two sections, a minimum of ten sections apart, in each of the 
naevus and control skin samples. The number of Ki-67 positive epidermal keratinocytes per unit length (µm) of 
basement membrane was determined by measuring the length of the basement membrane (section 2.3.3) and 
manually counting the positively stained cells. 
 
2.3.3 Image J analysis software program 
Images were analysed using the Image J (Image J, WCIF) for image analysis software program. The area of 
sample analysed and basement membrane length could be accurately calculated. Brightness and contrast could 















3.1 Optimisation of immunofluorescence (IF) protocol for selected antibodies 
The first objective of this study was to optimise the immunofluorescence (IF) protocol for each antibody 
selected. As detailed previously, naevus biopsy study samples consisted of archived specimens obtained from 
the NHLS that had been formalin-fixed and paraffin embedded (FFPE) at the time of naevus biopsy. 
Consequently, all antibodies required optimisation for use on FFPE tissue. Antibodies selected for analysis 
included: Melan-A, S100, Ki-67, OCT4, NANOG and p75. Optimised protocols are detailed in Table 4. Of note, 
antigen retrieval using a citrate buffer resulted in a high degree of background fluorescence when an Alexa-488-
conjugated secondary antibody was utilised. A Cy3-conjugated secondary antibody was thus preferentially 
selected for Melan-A, NANOG and p75 analysis. Dual staining for Melan-A/S100 and Melan-A/Ki-67 
necessitated the use of an Alexa-488-conjugated secondary antibody for S100 and Ki-67 analysis despite the 
increase in background fluorescence. OCT4 showed optimal staining using an EDTA buffer and an Alexa-488-
conjugated secondary antibody could be utilised with minimal background fluorescence. Regardless of the 
secondary antibody selected, all images were captured in both the Alexa-488 (green) and Cy3 (red) channel as 
composite images were found to better delineate the skin architecture. In addition, DAPI was used for OCT4 
and NANOG imaging and here images were captured in all three channels, with DAPI being visualised in the 
DAPI (blue) channel. DAPI, however, has been omitted from the below composite images to allow for better 
clarity of image. Only dual labelled cells (OCT4+/DAPI+ and NANOG+/DAPI+) were accepted as being true 
positive cells. 
 
3.1.1 Optimisation of Melan-A 
Results of Melan-A staining in control skin biopsies demonstrated Melan-A positive (Melan-A+) melanocytes 
within the basal layer of the epidermis (red arrows, Figures 7a, 7b). Staining was cytoplasmic and fine dendrites 
which projected into the epidermis were clearly visible (insert, Figure 7b). Non-melanocytic cells did not stain 
positively for Melan-A and no staining was seen in control samples where the primary antibody was omitted 
(Figure 7c).    
 
3.1.2 Optimisation of S100 
Results of S100 staining in control skin biopsies demonstrated S100 positive (S100+) epidermal melanocytes in 
the basal layer of the epidermis (red arrows, Figures 8a, 8b). S100 positive Langerhan’s cells were seen in the 
suprabasal layers of the epidermis (white arrows, Figures 8a, 8b). S100 staining was cytoplasmic and fine 
dendritic processes that projected into the epidermis were clearly visible (insert, Figure 8a). Other epidermal 
cells did not stain positively for S100 and no staining was seen in the control samples where the primary 














Figure 7: Optimisation of Melan-A immunostaining in FFPE human skin samples:  a, b: Melan-A+ melanocytes 
within the basal layer of the epidermis (red) (red arrows) and Ki-67+ epidermal keratinocytes (green) (blue arrows) using a 
dual staining technique. Non-specific fluorescence of collagen fibres is seen within the dermis (white arrows). Insert b: 
Cytoplasmic staining and clear dendrites. c: No Melan-A staining in sample where primary antibody omitted. E: indicating 
epidermis. D: indicating dermis. 
 
Figure 8: Optimisation of S100 immunostaining in FFPE human skin samples: a, b: S100+ basal melanocytes (red 
arrows) and suprabasal Langerhan’s cells (white arrows) (both green). Insert a: Cytoplasmic staining and clear dendrites.   
c: No S100 positivity in section where primary antibody was omitted. E: indicating epidermis. D: indicating dermis. 
 
Figure 9: Optimisation of Ki-67 immunostaining in FFPE human skin samples: a, b: Ki-67+ keratinocytes in the 
suprabasal layer of epidermis (green) (blue arrows), predominantly paired, and Melan-A+ melanocytes in the basal layer of 














3.1.3 Optimisation of Ki-67 
To identify proliferating cells, and to establish whether it is possible to detect dividing melanocytes, a dual 
labelling technique for Melan-A and Ki-67 was performed on control samples of normal human skin. Results 
demonstrated Ki-67 positive (Ki-67+) keratinocytes within the basal and suprabasal layers of the epidermis 
(blue arrows, Figures 9a, 9b), with positive staining cells often occurring in pairs. No staining was seen in the 
control samples where the primary antibody was omitted (Figure 9c). Two sections of normal human skin, both 
obtained from the same individual, each showed a dual positive (Melan-A+/Ki-67+) melanocyte in the basal 




Figure 10: Dual labelling for Melan-A (red) and Ki-67 (green) in FFPE human skin samples: a, d: Composite images 
showing Melan-A+/Ki-67+ epidermal melanocytes (arrows). Insert a, d: Co-localisation of signals, enlarged view. b, e: 
Single channel images showing Ki-67+ melanocytes (arrows).  c, f: Single channel images showing Melan-A+ melanocytes 
(arrows). E: indicating epidermis. D: indicating dermis. 
 
3.1.4 Optimisation of OCT4 
The objective of this experiment was to generate a positive “tissue” control for OCT4 immunostaining. Mouse 
ES cells were cultured as described in materials and methods (section 2.1.3) and formed well defined colonies. 













11a, 11b). As colonies matured and began to differentiate, they exhibited a larger size and a flattened, less well-




Figure 11: Morphology of mES colonies under light microscopy. a, b: Small, rounded, well-defined pluripotent colonies 
with a bright border. c, d: Flattened, poorly defined colonies which have started to differentiate and expand into the 
surrounding feeder layer.  
 
Cultured mES cell colonies were then subject to immunofluorescence analysis and showed positive OCT4 
expression in the nuclei of mES cells (Figure 12a). Nuclear localisation was confirmed by co-localisation with 
the nuclear stain DAPI (not shown here). Some nuclei did not show OCT4 positivity (white arrows Figure 12a). 
Underlying iMEF cells did not stain positively for OCT4 (internal negative control, red arrows Figure 12a) and 
no OCT4 staining was seen in the control sample where primary antibody was omitted (Figure 12b).  
 
Once colonies were shown to express OCT4, cultured mES cells were lifted with dispase and subject to careful 
trituration to generate a single cell suspension, and then subject to formalin-fixation and wax impregnation (as 
detailed in materials and methods, section 2.2.3.2[b]).  Results showed OCT4 positive (OCT4+) nuclei of mES 
















Figure 12: OCT4 expression in cultured mES cell colonies by immunocytochemistry: a: An OCT4+ mES cell colony 
(green) showing positive nuclear staining. Some nuclei appear elongated and/or flattened in areas of high cell density. Some 
mES cells did not display OCT4 positivity (white arrows). Background iMEF cells stain negatively for OCT4 and are 




Figure 13: OCT4 expression in FFPE mES cells: a, b: OCT4+ mES cells visualised by Cy3- and Alexa-488-conjugated 
secondary antibodies respectively (red and green correspondingly), showing nuclear localisation of signal. c: No staining is 




Figure 14: Optimisation of OCT4 immunostaining in FFPE human skin samples: a: OCT4+ epidermal keratinocytes 
following Citrate mediated antigen retrieval (red). B: Negative epidermal staining when an EDTA buffer was used. E: 













OCT4 expression was then examined in normal skin biopsies to further optimise the IF protocol for FFPE 
human skin. The aim was to eliminate non-specific binding of this antibody in processed skin and thus exclude 
false positive results. When HIER using a citrate buffer was performed, the majority of epidermal keratinocytes 
appeared positive for OCT4 (Figure 14a), indicating non-specific background staining. This non-specific 
binding was eliminated when and EDTA buffer was utilised (Figure 14b). Both Citrate and EDTA mediated 
antigen retrieval resulted in optimal OCT4 immunostaining in cultured mES cells and an EDTA buffer was thus 
selected for antigen retrieval in naevus samples. Interestingly, although stem cell niches have been described in 
both the basal layer of the epidermis and in the dermis of murine skin (Amoh et al, 2005; Fernandes et al, 2004, 
2007; Li et al, 2009; Nishimura et al, 2002; Sieber-Blum et al, 2004; Toma et al, 2001; Wong et al, 2006), 
further subsets of OCT4 positive epidermal and/or dermal cells were not seen in normal human skin in this 
study. No staining was seen in control samples where primary antibody was omitted (not shown here). 
 
3.1.5 Optimisation of NANOG 
As for OCT4, the first objective of NANOG optimisation was to generate a positive “tissue” control. The 
NANOG antibody used in this study did not cross-react with mouse ES cells and thus induced pluripotent (iPS) 
cells of human origin were used as a positive control (materials and methods section 2.1.11). Immunostaining of 
human iPS cell colonies (Figure 15a) showed positive NANOG expression in the nuclei of iPS cells. Nuclear 
staining was diffuse and clear nucleoli were visualised. Nuclear localisation was confirmed by co-localisation of 
the nuclear stain, DAPI (Figure 15b). Nuclei were not uniformly round or oval in shape and appeared flattened 
and/or elongated in areas of high cell density. Some nuclei did not show NANOG positivity (white arrows 
Figure 15a). Underlying iMEF cells did not stain positively for NANOG (internal negative control, yellow 
arrows Figure 15a) and no staining was seen in control samples where primary antibody was omitted (Figure 
15c).  
 
Human iPS colonies could not be generated in sufficient quantities to generated FFPE samples of cultured cells 
and thus NANOG optimisation for FFPE tissue was carried out in normal human skin biopsies according to 
manufacturer’s recommendations (Abcam, USA). Results of NANOG immunostaining showed a subset of 
NANOG positive (NANOG+) cells within a sebaceous gland (Figure 16a). In addition, a single NANOG+ cell 
was seen within the basal layer of the epidermis (Figure 16b) in a second section. No staining was seen in 















Figure 15: NANOG expression in human iPS cell colonies evaluated by ICC: a: NANOG+ human iPS cell colony (red). 
Staining is nuclear and nucleoli are clearly visible. DAPI positive nuclei of the same iPS colony are shown in b. Some iPS 
cells did not show NANOG positivity (white arrows a, b). Similarly, underlying iMEFs acted as an internal negative control 
and demonstrated positive DAPI signal but did not express NANOG (yellow arrows a, b). c: No staining is seen in control 




Figure 16: Optimisation of NANOG immunostaining in FFPE human skin samples: a: NANOG+ cells (red) within a 
sebaceous gland. b: A single NANOG+ cell (red) within the basal layer of the epidermis (arrow). c: No staining in control 




Figure 17: Optimisation of p75 immunostaining in FFPE human skin samples: a: Positive p75 expression in the 
epineurium and perineurium of dermal nerves (red). b: No staining is seen in control sample where primary antibody has 
been omitted. A neurovascular bundle is seen in the top right: nerve (yellow arrow), artery (red arrow) (two autofluorescent 













3.1.6 Optimisation of p75 
Results of p75 immunostaining showed positive p75 expression in the epineurium and perineurium of dermal 
nerves (Figure 17a). P75 positive (p75+) cells were not noted in any other skin compartment (internal negative 
control) and no staining was seen in control samples where primary antibody was omitted (Figure 17b).  
 
To ensure protocols for optimisation were comparable between cultured cells and FFPE skin samples, p75 was 
also optimised for cultured neurospheres (materials and methods, section 2.1.7).  In brief, mES cells were 
seeded on iPA6 feeder layers and small, spherical colonies began to lift from the underlying feeder layer by day 
14 and float freely in suspension (Figure 18). Once in suspension, neurospheres were seen to propagate by 




Figure 18: Neurospheres grown in suspension from mES cell colonies: a, b: Neurospheres grew in suspension as tightly 





Figure 19: Optimisation of p75 immunostaining in FFPE neurospheres: a, b: p75+ neurospheres (green) which have 
been FFPE. c: No staining is seen in the FFPE control sample where primary antibody has been omitted. 
 
Cultured neurospheres were first evaluated for p75 expression by ICC (materials and methods, section 
2.2.3.2[a]) and showed positive staining for p75. No staining was seen in control samples where primary 
antibody was omitted (results not shown here). Cultured neurospheres were then subject to formalin-fixation and 













skin samples, processed neurospheres showed positive p75 staining (Figure 19a, 19b). Again, no staining was 
seen in control samples where primary antibody was omitted (Figure 19c).  
 
3.2 Histological analysis of FFPE naevus biopsy study samples 
Naevus biopsy samples were obtained from the National Health Laboratory Services (NHLS) archives. All 
specimens were analysed by a qualified anatomical pathologist at the time of naevus biopsy. Only specimens 
with a proven histopathological diagnosis of benign melanocytic naevus were included in this study. For each 
specimen, a single section was analysed using a standard histological stain (Figure 20) and this was utilised to 
orientate the IF images and to ensure data analysis was performed on representative areas of naevus cells only.  
 
In total, ten naevus specimens were included in this study. Two samples from five different subtypes were 
included. These consisted of (i) junctional (Figures 20a, 20b), (ii) compound (Figures 20c, 20d), (iii) benign 
intradermal naevus (BIN) (Figures 20e, f), (iv) blue (including one cellular blue naevus and one epithelioid blue 
naevus) (Figures 20g, 20h respectively) and (v) dysplastic (Figures 20i, 20j). The characteristics of each naevus 














    Figure 20: Histological analysis of naevus samples (H&E):  
a, b:Junctional naevi, showing epidermal naevus nests at the tips of the  
rete ridges (arrows). c, d: Compound naevi, showing epidermal and  
dermal nests. e, f: Benign intradermal naevi (BIN), showing dermal  
infiltrates (arrows). g, h: Blue naevi, showing dense dermal infiltrates.  
Cells of the cellular blue naevus (g) retain dendrites and more  
closely resemble epidermal melanocytes, while cells of the epithelioid  
blue naevus (h) display a more rounded morphology and dendrites  
are not easily visialised. Of note is the presence of large amounts of dermal  
melanin. i, j: Dysplastic naevi, which show merging of the rete ridges  
(black arrows) and atypical melanocytes in the suprabasal layers of the  














Table 6: Patient clinical information and histological subtype of naevus samples: (-) designates unknown fields (not 
documented in folder or folder not existent). 
N ..... Histological Ageat Sa Site - ... Clinical Historyo' Sample Subtype Biopsy <mm) Pn:sen.tatiOD aDd naevil 
(y .... ) ReasooforRemoval meIaoomaan.d 
othertumoU1'5 
I (""e) 
I Junctional - - Thigh 5 Unllimn -
pigmentation. 
Regular border. 
Biopsied to exclude 
melanoma. 
2 Junctional 64 F Bock 3 Unllimn -
pigmentation. 
Irregular border. 
Reason:fur biopsy not 
reoonIed. 
3 Compound 52 F Thigh 4 Recent change in size Malignant blue 
andcolour(darker). naovus(37), 







4 Compound 51 F Foot 10 Dark pigmentation -
and irregular border. 
Biopsy to exclude 
melanoma. 
5 BIN 48 M Buttock 6 Removedaltime of Me1anoma.(48) 
concomitant 
me1anomaremoval. 
6 BIN 30 F Abdomen 3 Increase in size and Coogenital 
irregular border. naovusx2 (23), 
Biopsy to exclude BINand 
melanoma. derma1ofibroma. 
I (unknown) 
7 Blue - - Forearm 5 No change clinically -
priorto reoval, 
regular border. 
Biopsy to exclude 
melanoma. 




• Dysplastic - - - 9 Irregular border. Melanoma.-
Biopsy to exclude cm:rmtlybeing 
melanoma. trea1ed and file 
unavailable. 
10 Dysplastic 41 F Calf 9 Recent change in Multiple 
shape colour dysplastic:naevi, 














3.3 Immunofluorescence of benign melanocytic naevi 
3.3.1 Analysis of differentiation markers Melan-A and S100 
To examine the phenotype of a naevus cell, FFPE naevus samples were examined for the expression of 
differentiation markers Melan-A and S100 using a dual staining technique. A melanocytic phenotype was 
characterised by cells being Melan-A+ or by exhibiting dual positivity (Melan-A+/S100+), while cells of a 
potential Schwann cell phenotype were identified as being S100+ but Melan-A-, and occurring within naevus 
tissue. Potential Langerhan’s cells and dermal dendritic cells could not be excluded. A definitive myelinating 
Schwann cell phenotype was determined as being positive for both S100 and p75. This was determined by 
detecting the Melan-A-/S100+ cells in each sample and then staining the sequential section for p75. Expression 
of p75 by this Melan-A-/S100+ cell was examined (detailed in section 3.3.4 below). The association of a 
Schwann cell phenotype within naevi showing histological features of neurotisation was also evaluated. In 
addition, the distribution, orientation, and morphology of naevus cells were assessed in order to provide a 
general overview of morphology according to naevus subtype, and this also served as a template with which to 
orientate the sections when evaluating serial sections for Ki-67, p75, OCT4 and NANOG immunostaining.  
 
Results for Melan-A and S100 immunostaining confirmed the histological features of naevi. Typically, 
epidermal naevus cells occurred as discrete circular nests which localised to the tips of the rete ridges (Figures 
21a, 21b). Intervening naevus cells or melanocytes were few-to-none. Some samples showed a continuous 
proliferation of naevus cells with merging of adjacent epidermal nests and distortion of normal epidermal 
architecture (Figures 21c, 21d). The nests observed in such dysplastic subtypes were pleomorphic in 
morphology and fusion of the rete ridges with disruption of the normal epidermal architecture was marked. In 
addition, in dysplastic subtypes naevus cells were not restricted to naevus nests, but also occurred as single cells 
scattered haphazardly within the suprabasal layers of the epidermis, in keeping with the histological 
characteristics of dysplastic naevi (Figures 21e, 21f). Dermal naevus cells formed well circumscribed nests in 
the superficial/papillary dermis (Figure 21g), while those in the deeper/reticular dermis occurred more often as 
single cells. Specimen 4 and 6 showed histological features of maturation/neurotisation in H&E analysis and in 
keeping with this, naevus cells were seen to align vertically in cord-like structures in deeper dermal layers 
(Figure 21h), as previously described. 
 
Of interest, many naevus cells appeared to lie in pairs or “doublets” (Figure 21i, j). This was seen in all the 
naevus subtypes analysed and was observed within both the epidermal and dermal compartments. This 
characteristic “pairing” of naevus cells appeared to be a prominent feature of naevi and, when co-stained with 
Ki-67, these “paired” cells did not co-express Ki-67 thus recent cellular division could not be used to explain 
















Figure 21: Morphological patterns of naevi visualised by Melan-A (red) immunostaining: a, b: Melan-A+ naevus nests 
within the epidermis of a compound and junctional naevus respectively. Nests are discrete and localise to the tips of the rete 
ridges. A naevus nest is also seen within the superficial dermis (arrow, a). c, d: Naevus cells within the epidermis of a 
junctional and compound naevus respectively, showing merging of epidermal nests (arrows) and disruption of normal 
epidermal architecture. e, f: Naevus cells within the epidermis of a dysplastic naevus. Epidermal architecture is obliterated 
and single naevus cells are dispersed throughout the epidermis. Well circumscribed nests are present within the dermis 
(arrow, e). g, h: Dual labelling technique for Melan-A and S100. Split channel view showing Melan-A+ cells (red) and 
S100+ cells (green) within the superficial (g) and deep (h) dermis. Discrete nests are present within the superficial dermis 
(arrows, g), while deeper dermal cells arrange in a vertical orientation, forming cord-like structures (arrows, h). Melan-A 
expression is retained in the deeper dermal layers, despite morphological features of neurotisation. i, j: Dual labelling 
technique for Melan-A and Ki-67. Numerous “doublet” or “paired” Melan-A+ (red) naevus cells within the dermis and 
epidermis of a dysplastic naevus (arrows, i) and a BIN (arrows, j) respectively. Paired cells did not co-stain with Ki-67. A 
single Ki-67+ keratinocyte (green) (yellow arrow) can be seen in i. Individual naevus cells display a haphazard arrangement 















In assessing individual naevus cell morphology and orientation, dual labelled (Melan-A+/S100+) normal 
epidermal melanocytes localised to the basal layer of the epidermis and showed a regular orientation with their 
long axis lying along the basement membrane (refer Figure 7). In contrast, naevus cells showed a haphazard 
proliferation, with nuclei lying in all planes of orientation (refer Figure 21a-j). With the exception of blue naevi, 
dendrites were predominantly absent and/or obscured in areas of high cell density and naevus cells adopted a 
more rounded morphology (Figure 21a-j). The blue naevi analysed were of two differing subtypes, an 
epithelioid blue naevus and a cellular blue naevus. Similarly, these naevi showed Melan-A and S100 dual 
positivity at all dermal depths, regardless of their morphology. The epithelioid blue naevus (specimen 8) showed 
a rounded or “epithelioid” morphology and absent dendrites, in keeping with other naevus subtypes (Figure 
22a), and were similarly arranged as singular or small aggregates of cells, but not in typical nests. The cellular 
blue naevus (specimen 7) consisted of intradermal naevus cells with morphology similar to that of epidermal 
melanocytes and clearly visible dendrites (Figure 22b). Similarly, cells occurred singly, or in small clusters, 
within the dermis and no typical nests were noted. 
 
In evaluating naevus cell phenotype, Melan-A and S100 immunostaining demonstrated co-expression of Melan-
A and S100 in by far the majority of sections analysed. Occasional single staining cells were noted and these 
appeared to be specific to the epidermal compartment of naevi, where sporadic epidermal cells were noted to be 
either Melan-A+/S100- (white arrows, Figure 23a, 23c) or Melan-A-/S100+ (yellow arrows, Figure 23b, 23d), 
while the intradermal component of compound, BIN, blue and dysplastic naevi showed naevus cells which were 
consistently positive for both markers. Even in samples with features of neurotisation, the deeper dermal cells 
were found to retain their expression of Melan-A, thus retaining a melanocytic phenotype (refer Figure 21g, h). 
This differs from previously reported find ngs (Barnhill et al, 2004; Freedberg et al, 2003). In addition, S100+ 
but Melan-A- cells did not co-stain with p75 in serial section analysis indicating these S100+/Melan-A- cells 
cannot be ascribed a myelinating Schwann cell phenotype. 
 
Melan-A and S100 showed a similar sensitivity for normal epidermal melanocytes and naevus cell identification 
(discussed further below). Although both markers had a comparable sensitivity, Melan-A proved a superior 
marker with regards to specificity, as expected, as well as cell morphology. Using Melan-A immunostaining, 
nuclei were more clearly visible, cellular limits more easily definable and dendrites, when present, more easily 
visualised (Figures 23a, 23c); as compared to S100 immunostaining which resulted in less clear imaging on all 
three accounts (Figure 23b, d).  
 
Other points of interest include the observation of occasional single dermal melanocytes in the reticular dermis 

















Figure 22: Cellular morphology of blue naevi visualised by Melan-A (red) immunostaining: a: Naevus cells of an 
epithelioid blue naevus typically showed a rounded morphology with a loss of dendritic phenotype. Again, paired or 
“doublet” naevus cells are observed (arrows). b: Naevus cells of a cellular blue naevus showing a morphology more in 





Figure 23: Comparison of Melan-A and S100 immunostaining in FFPE naevus samples: a, c: Melan-A+ naevus cells 
(red) showing clear nuclei and distinct cellular borders. b, d: The same fields showing S100+ naevus cells (green). Cells 
borders are less distinct and nuclei l ss clearly visualised as compared to Melan-A. Not all Melan-A+ cells are S100+ 


















In an attempt to establish what proportion of naevus cells express Melan-A and/or S100, a semi-quantitative 
analysis was carried out as detailed in materials and methods (section 2.3.2). In brief, areas representative of 
naevus tissue, as determined by H&E and Melan-A immunostaining, were identified in ten high power fields 
(HPFs) of each neavus sample. An area within this was randomly selected and the total number of cells counted. 
The proportion of Melan-A or S100 positive cells relative to Melan-A or S100 negative cells respectively within 
the selected areas were then calculated and presented as a percentage of total cells counted (Figure 25a). In this 
semi-quantitative analysis, 85.36% of naevus cells stained positively for Melan-A and 84.15% for S100. The 
epidermal compartment of naevi, showed a relatively low proportion of Melan-A and S100 positive cells, as 
compared to other compartments (64.25% and 56.77% respectively) (Figures 25b, 25c respectively), and this 
low value was attributed to intervening keratinocytes within the epidermal naevus nests which did not stain 
positively for either marker and could not be excluded from the selected area due to their location within naevus 
tissue. The superficial dermal compartment showed the vast proportion of naevus cells staining positively for 
Melan-A and S100 (96.7% and 97.24% respectively). Similarly, the deep dermis showed Melan-A and S100 




Figure 25: Comparison of Melan-A and S100 immunolabelling in naevus biopsy samples according to naevus 
subtype (a) and cutaneous compartment (b, c). 
 
 
3.3.2 Analysis of proliferation marker Ki-67 
To determine whether proliferating naevus cells were present in the samples analysed, and to which 
compartment these cells localised, the proliferation marker Ki-67 was used in a dual labelling technique with 
Melan-A. Results of Ki-67 immunostaining showed dual labelled (Melan-A+/Ki-67+) cells within all naevus 
samples analysed (Figure 26), with the exception of one sample (sample 5). Dual labelled cells were most 















Figure 26: Dual labelling technique for Melan-A (red) and Ki-67 (green) in FFPE naevus biopsy samples: a-g: 
Melan-A+/Ki-67+ cells within the epidermis of junctional (a, b), compound (c), blue (d) and dysplastic (e, f, g) naevi 
(arrows). h, j: Melan-A+/Ki-67+ cells within the dermis of a compound and BIN respectively (arrows). Inserts a-i: Dual 
labelled naevus cells, enlarged views. Yellow line (d) indicates dermo-epidermal junction (dermo-epidermal junctions of 
other images more easily visualised). 
 
 
In an attempt to establish what proportion of naevus cells express Ki-67, a semi-quantitative analysis was 
carried out as detailed in materials and methods (section 2.3.2) and previously described for Melan-A and S100 













naevus cells counted was determined and results are shown in Figure 27. Junctional naevi contained the highest 
proportion of dual labelled naevus cells (1.54%), closely followed by dysplastic naevi (1.26%). Compound, blue 
and BIN exhibited less dual positivity (0.8%, 0.53% and 0.14% respectively) (Figure 27a). As mentioned above, 
the epidermal compartment contributed the vast majority of dual labelled cells (Figure 27b). Of the total Melan-
A+/Ki-67+ cells counted, the epidermal compartment contained 76.17%, while superficial dermis and deep 




Figure 27: The proportion of dual labelled (Melan-A+/Ki-67+) naevus cells in the epidermis (blue), superficial 
dermis (green) and deep/reticular dermis (red) relative to the total number of Melan-A+ naevus cells counted, 
stratified according to naevus subtype (a) and cutaneous compartment (b).  
 
Naevus samples analysed showed a large proportion of Ki-67+ keratinocytes within the epidermis of naevus 
tissue (Figure 28a, b). This prompted the comparison of Ki-67+ keratinocytes within naevus tissue, as compared 
to normal skin and described in materials and methods. Briefly, five HPFs in each naevus sample (ten naevus 
samples) and five HPFs in normal human skin (ten normal skin biopsies) were selected for analysis. Each HPF 
selected contained epidermal tissue and the total number of Ki-67+ epidermal keratinocytes per field were 
counted. In addition, the total length of basement membrane was determined for each field and results were 
expressed as the total number of Ki-67+ epidermal keratinocytes (x) per unit length of basement membrane in 
microns (x/µm). Results were comparable between naevus tissue and control skin (Figure 29), however, blue 
naevi surprisingly demonstrated a marked increase in Ki-67 positivity as compared to control skin and other 















Figure 28: Increased numbers of Ki-67+ epidermal keratinocytes (green) in FFPE naevus samples (a, b) as 




Figure 29: Proportion of total epidermal Ki-67+ cells per unit length of basement membrane (µm) in naevus 
subtypes and in normal skin.  
 
 
3.3.3 Analysis of pluripotency markers OCT4 and NANOG 
To determine whether pluripotent stem cells are present in naevus tissue, FFPE naevus samples were examined 
for expression of pluripotency markers OCT4 and NANOG. Nuclear localisation of both markers was confirmed 
by co-localisation with the nuclear stain DAPI. Only dual labelled cells (OCT4+/DAPI+ and NANOG+/DAPI+) 
were accepted as being true positive cells. 
  
3.3.3.1 OCT4 
Results for OCT4 immunostaining demonstrated the presence of OCT4+ cells within naevus tissue in seven of 
the ten samples analysed (sample 2, 3, 4, 6, 8, 9 and 10). In naevus tissue with a low cell density, OCT4+ nuclei 
were of a similar morphology to surrounding keratinocytes, while they appeared elongated and/or flattened in 
naevus tissue with a high cell density. This observation was similar to that observed for cells in high density 













In the epidermal compartment of naevi, OCT4+ cells occurred predominantly in clusters and were located 
towards the centre of the naevus nests (white arrows Figures 30a-c). These clusters were distributed throughout 
the length of the involved epidermis and are as prominent at the edge of the lesions as in the centre. This 
clustered pattern was most marked in dysplastic naevi. OCT4 positive cells were also seen to occur in pairs 
(yellow arrows Figures 30d-f, 30j) and as single cells (grey arrows Figures 30f, 30h-j). Single OCT4+ cells 
occurred more commonly at the periphery of the naevus nests where they would be expected to abut the 
basement membrane. Two single OCT4+ cells were also seen in the basal layer of normal intervening epidermis, 




Figure 30: OCT4+ cells (green) within the epidermal compartment of naevi. a-c: Clusters of OCT4+ cells within 
epidermal naevus nests (white arrows). d-j: OCT4+ cells occurring in pairs (yellow arrows) (d, e, f, j) and as single cells 
(grey arrows) (f, h, i, j), typically occurring toward the periphery of a naevus nest. a, g: Single OCT4+ cells in the basal 
layer of normal intervening epidermis (red arrows). Inserts: Enlarged views of OCT4+ cells. Of note: only cells showing 














In the dermal compartment of naevi, OCT4+ cells were only occasionally seen (samples 3, 4, 6, 8 and 10) and 
when present, localised to the superficial or papillary dermis (arrows Figures 31a-c). Here, OCT4+ cells 
occurred as pairs or as single cells and not within clusters as seen in the epidermis. Only one sample (sample 8) 




Figure 31: OCT4+ cells (green) within the superficial and deep dermal compartments of naevi: a-c: OCT4+ cells 
within the superficial dermis of a compound naevus (arrows). d: OCT4+ cells within the deeper reticular dermis of a blue 
naevus (arrows). Inserts: Enlarged views of OCT4+ cells. 
 
In an attempt to establish what proportion of naevus cells express OCT4, a semi-quantitative analysis was 
carried out as detailed in materials and methods (section 2.3.2) and previously described for Melan-A and S100 
analysis (section 3.3.1). Results are shown in Figure 32. Dysplastic naevi showed the largest proportion of 
OCT4+ cells (5.81%) as compared with other subtypes analysed (Figure 32a). Compound naevi (2.13%), blue 
naevi (0.9%), junctional naevi (0.13%) and BIN (0.12%) showed a lower proportion of OCT4+ cells, but 
importantly, they still showed OCT4 positivity. Of the total number of OCT4+ cells identified, the greatest 
proportion occurred in the epidermal compartment of naevi (77.22%), while a far smaller proportion occurred in 




Figure 32: The proportion of OCT4+ cells per total naevus cells counted in the epidermis (blue), superficial dermis 














Results for NANOG immunostaining demonstrated the presence of NANOG positive (NANOG+) cells within 
six of the ten samples analysed (samples 2, 3, 5, 8, 9, and 10). The morphology of NANOG+ nuclei was similar 
to that described previously for OCT4+ nuclei and nuclei of high density iPS colonies (section 3.1.5).  
 
In the epidermal compartment of naevi, NANOG+ cells occur predominantly as single cells and not in clusters 
as seen with OCT4 immunostaining (arrows Figure 33). In addition, NANOG+ cells localised to the periphery 
of naevus nests. No centrally located NANOG+ cells were seen in the samples analysed. In the dermal 
compartment of naevi, NANOG+ cells were rarely seen. Two samples (samples 9 and 10) each demonstrated a 
pair NANOG+ cells in the superficial dermis (Figure 34a, 34b). One sample (sample 5) demonstrated NANOG+ 
cells within the reticular dermis (Figure 34c). NANOG+ cells were occasionally visualised in the sebaceous 
glands associated with naevus tissue (not shown) and a single NANOG+ cell was seen to occur in the reticular 
dermis (sample 8) adjacent to naevus tissue (Figure 34d). Of interest, NANOG+ cells did not appear to co-
localise with OCT4+ cells as determined by sequential section analysis.  
 
 
Figure 33: NANOG+ cells (red) within the epidermal compartment of naevi: a-e: NANOG+ cells (white arrows) within 
epidermal nests of a compound (a), dysplastic (b) and junctional (c, d, e) naevus, typically lying toward the periphery of 















Figure 34: NANOG+ cells (red) in the dermal compartment of naevi: a, b: NANOG+ cells within the 
superficial/papillary dermis of a junctional naevus (white arrows), occurring commonly in pairs. c: NANOG+ cells within 
the reticular dermis of a BIN (white arrows). d: A NANOG+ cell in the normal adjacent normal reticular dermis of a blue 
naevus (arrow).  
 
In an attempt to establish what proportion of naevus cells express NANOG, a semi-quantitative analysis was 
carried out as detailed in materials and methods (section 2.3.2) and previously described for Melan-A and S100 
analysis (section 3.3.1). Results are shown in Figure 35. Junctional naevi and dysplastic naevi contain the 
highest proportion of NANOG+ cells relative to total number of cells counted (1.3% and 1.14% respectively, 
Figure 35a). Compound, BIN and blue naevi contain a lower proportion of NANOG+ cells (0.37%, 0.36% and 
0.11% respectively), but importantly, still show NANOG positivity. Similarly to OCT4 immunostaining, of the 
total number of NANOG+ cells identified, the greatest proportion occur in the epidermal compartment of naevi 
(63.72%, Figure 35b), while a far smaller proportion occur in the superficial and deeper dermal compartments 
(21.95% and 14.33% respectively). Interestingly, dysplastic naevi show a greater proportion of NANOG+ cells 















Figure 35: The proportion of NANOG+ cells per total naevus cells counted in the epidermis (blue), superficial 




3.3.4 Analysis of neural crest marker p75 
To determine whether cells of a neural crest phenotype are present in naevus tissue, naevus biopsy samples were 
examined for the expression of the neural crest marker p75. Results for p75 immunostaining show the presence 
of p75 positive (p75+) cells within seven of the ten naevus samples analysed (samples 1, 2, 3, 4, 8, 9 and 10). 
The two benign intradermal naevi (samples 5 and 6) did not show p75 positive cells within naevus tissue in this 
study. P75 staining was cytoplasmic in localisation and cells were of a similar size and morphology to 
surrounding naevus cells. 
 
In the epidermal compartment of naevi, p75 positive cells occurred as single cells and in clusters, usually within 
the centre of naevus nests. These cells showed and irregular cell border which was thought to reflect 
intercellular adhesions (Figures 36a, 36b). In the dermal compartment of naevi, p75+ cells had a more regular, 
rounded phenotype and occured as single cells (Figures 36c-f). No clusters of p75+ cells were seen. p75+ nerves 
were seen in the dermis of all naevus samples analysed and confirmed the adequacy of immunostaining (Figure 
















Figure 36: p75+ cells (red) within the epidermal and dermal compartment of naevi: a-c: p75+ cells within the 
epidermis of a junctional naevus (arrows). Staining is cytoplasmic and cells display an irregular cellular border. A more 
rounded, regular cell border is seen in c. d-f: p75+ cells within the dermis of a blue naevus (d) and dysplastic naevi (e, f) 
(arrows). Inserts: Enlarged view of p75+ cells. g: p75+ dermal nerves provided an internal positive control.  
 
In an attempt to establish what proportion of naevus cells express p75, a semi-quantitative analysis was carried 
out as described in materials and methods (section 2.3.2) and previously described for Melan-A and S100 
analysis (section 3.3.1). Results are shown in Figure 37. Junctional naevi showed the largest proportion of p75+ 
cells relative to total number of cells counted (0.62%, Figure 37a), followed by compound and dysplastic naevi 
(0.43% and 0.37% respectively). Blue naevi showed a smaller proportion of p75+ cells (0.13%), but did show 
p75 positivity. As mentioned above, BIN showed no p75+ cells in this study. As for OCT4 and NANOG 
immunostaining, of the total number of p75+ cells identified, the epidermis contained the greatest number 
(57.15%, Figure 37b), while the superficial dermis and the deep dermis contributed to a lesser extent (35.71% 
and 7.41% respectively). Interestingly, in dysplastic naevi the superficial compartment alone contained p75+ 
cells. This is similar to that reported for NANOG immunostaining above.  
 
Overall, the epidermis contained the greatest proportion of all positively labelled precursor cells (OCT4, 
NANOG and p75 combined), contributing 72.72% (Figure 38a). More than half of all positive cells were 
















Figure 37: The proportion of p75+ cells per total naevus cells counted in the epidermis (blue), superficial dermis 




Figure 38: The combined proportion of precursor cells (OCT4+, NANOG+ and/or p75+) per total naevus cells 














4. DISCUSSION  
Melanocytic neoplasia is a multifaceted process which involves a complex interplay of genetic and 
environmental factors. Despite recent advances, the aetiology and pathogenesis of melanocytic neoplasms 
remains unclear and the anatomical location and state of differentiation of the initiating cell remains to be 
identified. It has recently been proposed that cancer may arise from a precursor cell which persists in adult 
tissues, and partakes in normal tissue homeostasis and repair. It is hypothesized that, should this cell undergo a 
mutational event either in utero or postnatally, subsequent recruitment of this cell during life may result in 
uncontrolled proliferation and ensuing tumour formation. This is known as the tumour stem cell hypothesis and 
advocates that tumours arise from stem-like cells and not from mature tissue elements.  
 
In considering the aetiology and pathogenesis of melanocytic neoplasms, and the potential role of stem cells in 
this process, there are two critical concepts which remain undefined and hamper our understanding of these 
disorders. Firstly, “naevomelanocytes” or “naevus” cells are poorly defined in current literature and, whether 
they represent a type of melanocyte in differing ages or stages of evolution, or whether naevus cells are a 
distinct cellular lineage, remains undetermined. Secondly, there is much disparity regarding the existence and 
phenotype of melanoma stem cells and hence the roles these tumour stem cells play in melanoma development. 
It has been suggested that this lack of clarity may result from variations in methodologies used to study such 
cells in culture, as well as in vivo influences such as the tumour microenvironment and immune system 
response, as each of these may impact on the frequency and phenotype of melanoma stem cells (as reviewed by 
Girouard and Murphy 2011; Gupta et al, 2009; Kennedy et al, 2007). The overall aim of this study was to 
evaluate the aetiology and pathogenesis of melanocytic neoplasms using the benign melanocytic naevus as a 
model system. First, the phenotype of a “naevus” cell was examined in order to characterise the possible lineage, 
and hence potential cell of origin, of these tumour cells (Section 1). Secondly, the proliferation of naevus cells 
was examined in order to extrapolate a possible compartment of origin of naevi (Section 2). Lastly, the 
hypothesis that melanocytic naevi may originate from a pluripotent or neural crest-like stem cell and not via de-
differentiation from a mature epidermal melanocyte was tested (Section 3).  
 
Section 1: 
4.1 The phenotypic characterisation of a “naevus” cell  
The benign melanocytic naevus is characterised histologically by proliferations of cells which arrange in defined 
clusters known as “nests”. Benign naevus cells are thought to represent a type of melanocyte but the exact 
relationship between normal melanocytes and benign naevus cells remains unclear as they show important 
morphological differences. Consequently, the cells of a naevus have been referred to as “nevomelanocytes” or 
“naevus” cells and their origin and following pathogenesis remains under question. Existing hypotheses propose 













cells into the dermis (Unna, 1893), while others propose naevi originate from a mutated precursor cell which 
persists in the post-natal dermis (Kawamura, 1956; Mishima, 1965 and Cramer 1984). Combining these 
theories, a dual origin of naevi has also been proposed where it is suggested that the epidermal component of 
naevi arises from a mutated epidermal melanocyte, while the intradermal component from a mutated Schwann 
cell (Masson, 1951).  
 
Contributing to the uncertainty surrounding the origin of naevi, naevus tissue has been shown to stain with many 
melanocyte specific markers such as tyrosinase, TRP1 and Melan-A/MART-1 (Sheffield et al, 2002; Snyder and 
Paulino, 2002), while subsets of naevus cells have been shown to stain negatively for these melanocytic specific 
markers, but positively for Schwann cell markers such as S100 or p75 (Barnhill et al, 2004; Freedberg et al, 
2003). To date, these studies have focused on the sensitivity of various markers in detecting naevus or 
melanoma cells, in order to identify a marker or panel of markers which will accurately diagnose melanoma and 
minimise false negative results. These studies have not, however, aimed to provide a detailed analysis of the 
distribution and/or overlap of markers within naevus and/or melanoma tissue which may allow for better 
phenotypic characterisation. This, in turn, may contribute to a better understanding of the cell of origin and 
subsequent pathogenesis of melanocytic neoplasms.   
 
To re-examine the staining characteristics of naevus tissue, and to provide a thorough evaluation of naevus 
markers in an attempt to accurately establish the phenotype of a naevus cell, ten human naevus biopsy samples, 
of five different naevus subtypes, were examined for the expression of select melanocyte and/or Schwann cell 
differentiation markers. Melan-A positive cells, with or without S100 positivity, were designated a melanocytic 
phenotype. S100 positive but Melan-A negative cells were indeterminate and could be Schwann cells, other 
S100 positive cells such as Langerhan’s cells or dermal dendritic cells, or a melanocytic cell which simply did 
not stain with Melan-A due to the limited sensitivity of this marker. To fully evaluate whether S100 positive but 
Melan-A negative cells could be Schwann cells, serial sections were examined for the expression of p75, 
whereby co-expression of S100 and p75 would confer a true Schwann cell identity. Furthermore, p75 positive, 
but S100 negative, cells would suggest a neural crest precursor phenotype (further discussed in section 3). 
 
4.1.1 Do “naevus” cells display a melanocytic phenotype? 
In this semi-quantitative analysis, 85.36% of naevus cells stained positively for Melan-A and, since Melan-A is 
a melanocyte differentiation antigen which is a highly sensitive and specific for skin melanocytes (Sheffield et 
al, 2002; Snyder and Paulino, 2002), these results were highly indicative of a melanocytic lineage. Results 
further showed that 84.15% of all naevus cells stained positively for S100, which shows a similar sensitivity to 
that seen for Melan-A. S100 has previously been considered the most sensitive marker for differentiated 
melanocytes, yet its lack of specificity has limited its use as a single diagnostic marker (Sheffield et al, 2002; 













reported findings. In addition, Melan-A proved a superior marker to S100 when evaluating naevus cell 
morphology. Melan-A showed improved cellular detail, including nuclei being more distinct, cellular borders 
more easily definable and dendrites, when present, more easily visualised. These results would suggest that, in 
formalin-fixed and paraffin-embedded naevus tissue, Melan-A is a superior maker to S100 in morphological 
evaluation, and displays a similar sensitivity.  
 
Although naevus cells were shown to express melanocyte specific markers, the morphology of naevus cells was 
markedly different to that of normal skin melanocytes, in keeping with previous views of naevus cells being 
“altered” melanocytes or a melanocyte in differing stages of evolution. In this study, naevus cells showed a 
haphazard organisation, lying in all planes of orientation and occurring in tightly clustered nests which resulted 
in the loss of their normal anatomical relationships with surrounding keratinocytes and the basement membrane. 
Dermal naevus cells exhibited a rounded morphology, did not have dendrites and show a decrease in size at 
deeper dermal levels. Specimen 4 and 6 showed histological features of maturation/neurotisation in H&E 
analysis and in keeping with this, naevus cells were seen to align vertically in cord-like structures in the reticular 
dermis. The above was in keeping with previous findings but, important to our understanding of the phenotype 
of these cells, these results confirmed essential differences between a neavus cell and a differentiated epidermal 
melanocyte.  
 
Of interest, a large proportion of naevus cells appeared to lie in pairs or “doublets”. These doublets did not co-
stain with Ki-67 and thus recent cellular division could not be used to explain this phenomenon. It is possible 
that these cells are slow-dividing cells which have previously divided but remain close together. 
 
In contrast to banal and dysplastic naevi which showed important morphological differences to melanocytes, the 
cells of a cellular blue naevus showed a dermal collection of cells which more closely resembled an epidermal 
melanocyte. Cells of a cellular blue naevus remained as single cells, did not aggregate to form nests and retained 
their dendrites. Although melanin production was not evaluated in this study, the production of melanin is a 
known characteristic of blue naevi and it is this accumulation of dermal melanin which imparts their blue hue 
clinically. This would suggest that cellular blue naevi are distinct from other naevus subtypes. Cells of the 
epithelioid blue naevus showed a similar single cell infiltrate, however, cells were more rounded in appearance 
and dendrites were absent. This subtype may represent an intermediate subtype. Furthermore, the epidermal 
keratinocytes in both blue naevus samples surprisingly demonstrated a marked increase in Ki-67 positivity as 
compared to control skin and other naevus subtypes. This implies an element of epidermal proliferation exists in 
addition to dermal melanocytic proliferation. This may suggest discrete mechanisms are involved in the 
development of blue naevi and that blue naevi may well have a different aetiology and pathogenesis to other 
naevus subtypes. In keeping with this, Ariyanayagam-Baksh et al (2003) demonstrated the rarely occurring 













melanoma. They concluded that malignant blue naevi may reflect a distinct entity with different molecular 
pathways of tumorigenesis to that of conventional melanoma.  
 
4.1.2 Was there any evidence for a Schwann cell phenotype within naevi analysed? 
As discussed previously, subsets of naevus cells have been shown to stain positively for Schwann cell markers 
such as S100 or p75, while staining negatively for melanocytic specific markers (Barnhill et al, 2004; Freedberg 
et al, 2003), indicating a potential Schwann cell phenotype. In this study, occasional S100+ but Melan-A- cells 
were identified within naevus tissue. To fully evaluate whether these S100+/Melan-A- naevus cells could be true 
Schwann cells, serial sections were examined for the expression of p75, where co-expression of S100 and p75 
would confer a true Schwann cell identity. P75 co-expression was not noted in these S100+/Melan-A- cells, and 
thus a true myelinating Schwann-cell phenotype (S100+/p75+) was not observed. Due to the non-specificity of 
S100 staining, these S100+/Melan-A- cells could be Langerhan’s cells or dermal dendritic cells which are 
normally present in human skin. In addition, Melan-A has been reported to be less sensitive than S100 and these 
S100+/Melan-A- cells may well be melanocytic cells which did simply not stain with Melan-A.  
 
Interestingly, previous studies have shown a loss of Melan-A expression in deeper dermal naevus cells, and the 
retention of Schwann cells markers which suggests naevus cells in the reticular dermis may display a Schwann 
cell phenotype.  In this study, naevus cells in the reticular dermis did not show a loss of Melan-A expression, 
even in the naevi which were histologically confirmed to show features of neurotisation. This indicates a 
melanocytic phenotype was maintained at all dermal levels, in opposition to previously reported findings 
(Mishima, 1965; Winnepenninkx and van den Oord, 2004).  
 
Section 2: 
4.2 The compartment of origin of naevi 
Most available data on melanocytic naevi are reports from static, cross-sectional analyses from naevus biopsy 
specimens. Thus, the step wise evolution of naevi remains unclear and evidence to support existing hypotheses 
is limited. The main question is whether naevi originate from the epidermis, and whether this is from a 
melanocyte or a precursor cell; or whether they arise from the dermis, and similarly whether this is from a 
Schwann cell, a “trapped” melanocyte, or a precursor cell (Masson, 1951; Kawamura, 1956; Mishima, 1965; 
Unna, 1893; Cramer 1984; Grichnik et al, 2006, Grichnik, 2008 and Ross et al, 2011). It follows that if the 
compartment of origin of naevi can be established, the possible initiating cell may then be determined. To date, 
studies evaluating Ki-67 immunostaining in melanocytic neoplasms have focused on the diagnostic value of Ki-
67 in assisting to differentiate between melanoma and naevus tissue. Higher proliferative rates are thought to 
favour a malignant diagnosis while lower proliferative rates are thought to favour a benign diagnosis (Li et al, 
2000). Similarly, Ki-67 positivity in deeper dermal levels is more commonly seen within melanoma tissue and 













whereby increased proliferative rates in melanoma biopsies are associated with an increased risk of metastases 
(Gimotty et al, 2005). Little data, however, exists for the qualitative description of Ki-67 positivity within naevi 
which may well point to an initiating or driving focus. To re-examine Ki-67 immunostaining in naevus tissue 
and to attempt to determine a possible compartment of origin of naevi, the same ten human naevus biopsy 
samples were examined using a dual labelling technique for Melan-A and Ki-67 in order to detect dividing 
naevus cells. It was hypothesised that areas of Ki-67 positivity may indicate foci driving naevus proliferation, 
and thus be a potential site of naevus initiation.  
 
4.2.1 Which compartment drives naevus proliferation? 
In this semi-quantitative analysis 76.17% of dual labelled (Melan-A+/Ki-67+) naevus cells were located in the 
epidermal compartment. Junctional and dysplastic naevi contained the highest proportion of dual positive cells 
per total Melan-A+ naevus cells counted (1.54% and 1.26%), while compound, blue and BIN showed lower 
proliferative rates (0.8%, 0.53% and 0.14% respectively). These results suggest that the epidermal compartment 
likely drives naevus proliferation and would therefore support an epidermal origin of naevi.  
 
In support of an epidermal origin of naevi, junctional naevi are thought to arise in childhood and progress to 
compound and finally intradermal naevi, which may then regress. It could be expected that proliferative rates 
would decrease with progression through these sequential subtypes. In keeping with this, junctional naevi 
displayed an increased proliferative rate as compared to compound naevi, which further decreased in BIN (refer 
Figure 27). This would support and epidermal origin with “dropping off” of these cells into the dermis and a 
possible mechanistic hypothesis. In addition, dysplastic naevi, which are really atypical compound naevi, 
showed a proliferative rate similar to that seen in junctional naevi. It is possible that dysplastic naevi contain a 
mutation which limits attempted differentiation along normal melanocytic pathways and eventual cessation of 
proliferation. This increased proliferative drive may be associated with their tendency to change with time due 
to accumulation of additional mutations, as well as their increased risk of malignant transformation.  
 
It must be considered, however, that since this is a single cross-sectional analysis, it is possible that the 
epidermis may drive naevus proliferation, yet not necessarily be a source of origin of the initiating cell. Thus the 
mechanisms of naevus development cannot be fully concluded from this study. 
 
4.2.2 Do naevi originate from a single cell or is there evidence for multiple sites of naevus initiation? 
An interesting observation when considering the origin of naevi, was that nests of naevus cells occurred as 
discrete clusters of cells at the tips of the rete ridges, separated by a normal intervening epidermis. This would 
suggest these naevi have multiple sites of initiation and the hypothesis, therefore, of a single mutated cell giving 
rise to, and subsequently driving, naevus proliferation cannot logically be used to explain this phenomenon. In 













drive naevus proliferation. In opposition to this, dysplastic naevi, and some compound naevi, showed a 
continuous proliferation of naevus cells and merging of adjacent epidermal nests, while BIN and blue naevi 
showed a continuous dermal infiltration. In these subtypes, the hypothesis of a single initiating cell was more 
easily believable. It is possible, therefore, that different mechanisms of pathogenesis may exist for different 
naevus subtypes. Some may develop following a local insult, such as changes in micro-environmental signalling 
and the generation of multiple simultaneous foci of initiation, while others may arise from a single mutated cell.  
 
4.2.3 Is naevus proliferation related to abnormalities in keratinocyte proliferation?  
Based on the above observations of multiple sites of naevus initiation, it was questioned whether some naevus 
subtypes may result from a local proliferative drive, the so-called field effect, rather than a single mutated cell. It 
is widely accepted that melanocyte proliferation is tightly regulated by surrounding keratinocytes and this 
functional relationship is important for optimal functioning and differentiation of both cell types. This is 
supported by co-culture systems, where keratinocytes have been shown to regulate melanocyte proliferation, 
dendricity and melanisation by direct cell contact (cell-to-cell adhesion molecules), as well as paracrine 
signalling molecules such as cytokines, growth factors and hormones (Herlyn et al, 1987; Hsu et al, 2002; Shih 
et al, 1994). This stresses the important role of local micro-environmental signals in controlling melanocyte 
phenotype and proliferation. It is thus feasible that changes in local environmental signals could drive naevus 
proliferation within a limited area in the skin and thereby explain multiple sites of naevus initiation within this 
site. It has also been proposed that naevi are simply hamartomas, a benign, focal malformation of normal tissue 
elements, which grow at the same rate as surrounding tissue, but grow in a disorganised mass. This would imply 
naevi would contain proliferations of other epidermal and/or dermal elements.  
 
Incidentally, the naevus samples analysed in this study showed a large proportion of Ki-67+ keratinocytes 
within the epidermis of naevus tissue (Figures 28a, 28b). This prompted the comparison of Ki-67+ keratinocytes 
within naevus tissue, as compared to normal skin, in order to determine whether a global proliferative effect was 
in fact present. The total Ki-67+ epidermal keratinocytes were determined per unit length of basement 
membrane in microns and this semi-quantitative analysis showed results were comparable between naevus 
tissue and control skin (Figure 29). This would indicate that naevi result from an isolated melanocytic drive, and 
does not support the hypothesis that naevi are true hamartomas. It is still possible, however, that local 
derangements in keratinocyte-melanocyte signalling may result in uncontrolled proliferation of cells of a 
melanocytic lineage. Surprisingly, however, the epidermis of blue naevi demonstrated a marked increase in Ki-
67 positivity as compared to control skin and other naevus subtypes (Figure 29) and, as discussed previously, 

















4.3 Evaluation of the tumour stem cell hypothesis in melanocytic naevi 
The basic steps of neoplasia involve initiation, promotion, progression and, occasionally, resolution. Tumour 
initiation involves a mutational event, within oncogenes or within tumour suppressor genes, which primes the 
cell to respond abnormally to normal growth signals or previously sub-threshold signals. It has recently been 
proposed that this initiating mutation may occur in a precursor cell and that this mutation may be inherited; or 
occur in utero, or postnatally. This is known as the tumour stem cell hypothesis and is based on the observation 
of a sub-population of cells with stem-like features within tumour cultures. 
 
Stem cells are slow proliferating cells characterised by the ability to maintain their undifferentiated state through 
self renewal and to give rise to differentiated cell types. At present, four types of stem cells have been described: 
embryonic stem cells, cancer stem cells, adult or somatic stem cells and induced pluripotent stem (iPS) cells. 
The overlap between these four cell types is ill-defined and importantly, the origin of a cancer stem cell and 
their relationship to an adult stem cell is unclear. Whether cancer stem cells originate from a mutated adult stem 
cell (Reya et al, 2001), from a mutated transit amplifying cell (Clarke and Fuller, 2006), or result from de-
differentiation from a terminally differentiated cell (Sun et al, 2005) remains unknown. Furthermore, not all 
cancer stem cells have the ability for indefinite renewal, as benign tumours such as banal naevi are known to 
undergo a period of growth which then stabilizes, and often regresses (Kincannon and Boutzale, 1999), implying 
an origin from a cell with a limited capacity for self-renewal and thus, by definition, not a true stem cell. 
Moreover, the occurrence of “de-differentiated” cells in malignant tissues, and the current lack of understanding 
as to the overlap between “de-differentiation” and “stemness”, further confuses this issue. 
 
At present, studies examining the presence and phenotype of stem cells within melanoma are based entirely on 
cell culture and have generated inconsistent results. Variations in methodologies used to study such cells in 
culture have been proposed as a cause, yet this has lead to much disagreement on the existence and/or role of 
stem cells in melanoma development. In situ studies may limit variations in study methodologies, as well as 
limiting the additional micro-environmental changes induced by culture conditions. However, since melanomas 
show histological similarities to a wide range of tumours which often makes accurate diagnosis challenging, 
current immunohistochemical analyses have focused on melanocytic differentiation antigens in order to 
accurately detect melanoma tissue and, to date, few immunohistochemical studies exist for the evaluation of 
stem cells or precursor cells in melanoma biopsies. As a result, to evaluate the tumour stem cell hypothesis in 
melanocytic neoplasms, and to do so involving limited micro-environmental changes, as well as to reduce the 
confusion surrounding the overlap between malignant “de-differentiation” and “stem cells”, we have selected to 
analyse the same ten human naevus biopsy samples by direct immunofluorescence in order to determine the 
presence, or absence, of precursor cells and to characterise these as neural crest stem cells (p75+) or pluripotent 













4.3.1 Did naevi contain precursor cells? 
Neural crest and pluripotent precursor markers were identified in all naevus subtypes analysed, with the 
exception of benign intradermal naevi which did not express p75. The majority of positively labelled cells, per 
total naevus cells counted, localised to the epidermal compartment (72.72%). This trend was evident for all three 
markers analysed: OCT4 (77.22%), NANOG (63.72%) and p75 (57.15%). It follows that naevi with an 
epidermal component (junctional, compound and dysplastic naevi) contained the majority of positively labelled 
precursor cells (a combined percentage of 91.67% of all positively labelled cells). Of these, dysplastic naevi 
contain more than half (52.27%) of all positive cells, and the vast majority of these expressed OCT4 (78.26%). 
Benign intradermal naevi and blue naevi contained fewer precursor cells, with a combined proportion of 8.33% 
of all positively labelled cells. Importantly, however, they did still contain precursor cells.   
 
Interestingly, OCT4+ cells localised mainly to the epidermal compartment and were seen to occur as small 
clusters of positively labelled cells within the centre of naevus nests, while NANOG+ and p75+ cells occurred 
as single cells at the periphery of naevus nests, and were slightly more evenly distributed between the epidermis 
and superficial dermis. Interestingly, NANOG immunostaining did not co-localise with OCT4, as determined by 
sequential section analysis. In human embryos, OCT4 has been detected in early blastocysts, while NANOG 
expression is only detected from the 8 cell blastocyst stage onwards (Kimber et al, 2008). Similarly, in porcine 
embryos OCT4 expression was detected in early embryos, persisted in early blastocyst and then decreased in 
expression around E9.5-E10.5. NANOG, however, was only detected at later stages of embryo development 
(E7.5) and persisted at high expression levels at E9.5 and E10.5 (du Puy et al, 2010). It thus appears that 
embryonic stem cells do not co-express OCT4 and NANOG at all stages of development. It could be 
hypothesized that the expression of OCT4 represents an early step in tumour formation and that these cells 
proliferate to form clusters of OCT4+ cells. As proliferation continues, cells are pushed laterally to the outer 
limits of the naevus nests where it appears NANOG expression is attained and expression of OCT4 is lost or 
down regulated to undetectable levels.  
 
Results of this study also showed that NANOG expression was more pronounced than OCT4 in cells in the 
superficial dermis. In keeping with the above line of thought, this could represent a later stage in tumour 
evolution, and supports the concept of an epidermal origin of naevi, with migration of cells from the epidermis 
to the superficial dermis. This is supported by Ki-67 staining patterns. Additionally, cells then may attempt 
further differentiation and gain the expression of p75. Consistent with this, p75+ cells displayed irregular cell 
borders which suggests the presence of intercellular adhesions (this pheomenon results from tissue distortion 
during procesing with widening of intercellular spaces. Intercellular adhesions are maintained and, as cells are 
pulled apart, they adopt an irregular, or “spiny” appearance as seen in Figures 36a, 36b). This would indicate 
p75+ cells are of a more differentiated phenotype as precursor cells lack intercellular adhesions. These p75+ 













melanocytes and in cells of a melanocytic lineage, is specific for a precursor phenotype. Thus, it is possible that 
these p75+ cells are neural crest precursors. It is also possible, however, that these p75+ cells are Merkel cells, 
which have been shown to express p75 in normal human skin (Lopez et al, 1998).  
 
4.3.2 Does evidence support stem cells as the origin of melanocytic naevi?  
Results of this study suggest an epidermal origin of naevi, as determined by Ki-67 immunostaining, and this is 
further supported by results showing naevus cells display a melanocytic phenotype, indicating origin from a cell 
of epidermal lineage. In addition, results demonstrated the presence of precursor cells within naevus tissue, the 
majority of which localise to the epidermis. Following this, the prominence of precursor cells within the 
epidermal compartment would suggest an association between epidermal melanocytic-lineage stem cells and 
naevus proliferation. This does not, however, provide evidence for the state of differentiation of the initiating 
cell. Whether naevus cells result from attempted differentiation of an epidermal precursor cell or from de-
differentiation from an epidermal melanocyte remains questionable.  
 
Clues as to the aetiology of naevi may be obtained from understanding normal melanocyte homeostasis; 
however, this remains a major challenge. A growing body of literature has established the role of stem cells in 
normal tissue maintenance and repair, and it is reasonable to assume that skin melanocytes are replenished from 
a reservoir of immature cells. It has been convincingly shown that melanocyte precursors do exist in postnatal 
skin. During normal hair cycling, hair follicle melanocytes are repopulated by a population of precursor cells 
residing in the hair follicle bulge (Nishimura et al, 2002; Sieber-Blum et al, 2004; Amoh et al, 2005; Wong et al, 
2006). These quiescent bulge precursor cells have been shown to downregulate melanocyte specific markers 
Mitf, TRP1, TRP2 (Dct) and Tyrosinase (Nishimura et al, 2010) and consequently, since discrete melanocyte 
stem cell markers have not yet been identified, detection of further melanocyte precursor populations is 
currently difficult. Maintenance of the interfollicular keratinocyte population has been shown to involve many 
small “units of proliferation” (Blainpan and Fuchs, 2009), which is independent of normal hair cycling. This 
would suggest that melanocytes too may be replenished from an interfollicular pool of precursor cells; and this 
is further supported by the observation of repigmentation of glabrous skin in conditions such as vitiligo (Davids 
et al, 2009). However, the presence of an interfollicular niche for melanocyte stem cells has not been 
definitively demonstrated.  
 
The potential for differentiated melanocytes to contribute to normal skin homeostasis is another possibility in 
maintaining the interfollicular melanocyte population, yet this hypothesis remains largely unexplored as 
dividing melanocytes have been difficult to demonstrate in samples of normal and/or wounded human skin. In 
this study, it was hypothesized that, should a naevus result from a precursor cell, it would require evidence for 
the existence of an interfollicular stem cell niche; or, should naevi result from an epidermal melanocyte, 













4.3.2.1 Is there evidence for the existence of an interfollicular stem cell niche? 
In this study, the epidermis of naevi contained the majority of proliferating naevus cells and this supports an 
epidermal origin of naevi. As discussed previously, 72.72% of all positively labelled precursor cells localised to 
the epidermal compartment of naevi and thus, if naevi originate from a precursor cell, this would imply the 
interfollicular epidermis is a potential precursor niche. Importantly, however, in this study only a single 
NANOG+ cell was identified in the basal layer of the epidermis of normal skin (Figure 16b). No further 
precursor cells were noted in the epidermis or dermis of normal human skin, or in the normal intervening 
interfollicular epidermis or dermis of naevi, as may have been expected. In keeping with this, Katona et al 
(2007) examined 115 cutaneous specimens, including a variety of benign and malignant epidermal neoplasms as 
well as normal skin, for OCT4 expression and demonstrated that all 115 specimens examined were negative for 
OCT4 expression as was adjacent or overlying epidermis and follicular epithelium including the bulge region. 
Tai et al (2005) examined a panel of 30 human normal tissue samples by immunohistochemical analysis and 
reported the finding of rare OCT4 positive cells within the basal layer of the epidermis. Results of this study 
were however unconvincing as the reported positive staining was difficult to perceive and an interfollicular 
niche remains to be definitively demonstrated.  
 
From the above, one could conclude that either an interfollicular stem cell niche does not exist and precursor 
cells result from terminally differentiated cells when required, or that precursor cells are present but, when 
housed in a specific niche, known pluripotency markers such as OCT4 and NANOG are downregulated and/or 
other currently unidentified markers are expressed. A number of stem cell markers exist which were not 
examined in this study. These may serve as important phenotypic markers of stem cells in human skin and may 
aid in identifying an interfollicular stem cell niche.  
 
4.3.2.2 Can normal epidermal melanocytes divide? 
In order to examine whether normal epidermal melanocytes are capable of in vivo cell division, normal human 
skin biopsies were evaluated with a dual labelling technique for Melan-A and Ki-67. Two dual labelled (Melan-
A+/Ki-67+) melanocytes were detected in normal skin epidermis (Figure 10). These dual labelled melanocytes 
were from two separate biopsy samples but interestingly, from the same patient. In addition to normal human 
skin, the normal epidermis adjacent to naevus tissue was examined for dual labelled cells. Dual labelled cells 
were occasionally present, yet because it was not possible to accurately confirm these were normal melanocytes 
and not distant naevus cells, they were not included in our results. The finding of Melan-A+/Ki-67+ 
melanocytes in normal human epidermis indicates that differentiated skin melanocytes are capable of 
undergoing cellular division. Thus it is entirely possible that differentiated melanocytes contribute to normal 
skin homeostasis and, if mutated may give rise to melanocytic neoplasms. In keeping with the above, Taylor et 
al (2011) showed the depletion of the overall melanocyte population in zebrafish was associated with an overall 













Also, melanocytes in culture show abilities to divide. These data, although greatly limited, support the concept 
that terminally differentiated melanocytes retain the ability to enter the cell cycle under certain micro-
environmental changes.  
 
It is therefore plausible that two separate pathways exist for melanocyte homeostasis, and central to this may be 
alterations in normal micro-environmental signals, such as MITF, which could control pathway switching. It 
follows that two pathways may exist for naevus development and that either precursor cells, or epidermal 
melanocytes, may give rise to melanocytic naevi and/or melanoma.  
 
4.3.3 Is there an association between naevus subtype, stem cell component and risk of melanoma 
development?  
Dysplastic naevi show histological features of architectural and/or cellular atypia, and are identified risk factors 
for the development of a melanoma. Of great interest, the dysplastic naevi analysed showed a very high 
proportion of OCT4+ cells (5.81%, Figure 32a), which was by far the greatest proportion of any precursor 
marker identified in this study. It is possible then that an increased stem cell component may contribute to an 
increased risk of malignant transformation. It can be hypothesised that cells of dysplastic naevi may have a more 
severe underlying mutation which may limit the cells ability to retain normal differentiation pathways and thus 
remain in a stem-like state. This stem-like state may result in the cellular atypia observed in these lesions, as 
well as confer and increased propensity to divide and therefore accumulate mutations, leading to an increased 
risk of malignant transformation. In keeping with this, dysplastic naevi contained a large proportion of Ki-67+ 
cells as compared to other naevus subtypes. The converse, however, is also feasible. It is possible that 
differentiated melanocytes undergo a mutational event which leads to the expression of various transcription 
factors resulting in an increased ability to “de-differentiate” and acquire a stem-like phenotype.  
 
4.4 Technical aspects and limitations of study 
Important in this study was the mastery of various techniques used to generate these results. The principal 
technique utilised was immunofluorescence and the challenge surrounded optimisation of each antibody for 
formalin-fixed and paraffin-embedded tissues. It is well recognized that formaldehyde fixation of tissues induces 
artefacts by cross-linking of amino acid residues which may lead to masking of tissue antigens and false 
negative results. Similarly, alteration of epitopes may lead to non-specific binding and false positive results. 
Many techniques have been employed to unmask these hidden epitopes and recover immunoreactivity. In this 
study, heat induced epitope retrieval proved the most successful method of antigen retrieval. However, complete 
certainty that all epitopes were detected, or not detected, is not possible. Given these limitations when 
performing immunohistochemistry, as well as the notorious difficulty in performing immunohistochemistry for 
pluripotency markers such as OCT4 and NANOG, alternative methods to validate the expression of these 













samples and analysis using techniques of real time PCR could provide a sensitive alternative technique to 
validate the above data. Demonstration that these markers exist within the naevus tissue itself, and not within the 
intervening epidermis or dermis would, however, be impossible to determine. A dual approach of in situ 
analysis for tissue localisation and PCR for improved sensitivity and specificity would be a superior approach.  
 
Dual labelling proved immensely difficult as tissue processing had to be balanced between optimised protocols 
for each antibody. This proved a time consuming task, but eventually successful dual labelling techniques for 
selected markers were achieved. The protocol for NANOG immunostaining was only able to be optimised for 
cultured cells and thus the protocols used for processed tissue may not have been optimal. Attempts to alleviate 
this were performed by ensuring the protocols optimised for p75 analysis in culture and in processed tissues 
were similar.  
 
The main limitation of this study was the inability to draw statistical comparisons. Firstly, the sample size was 
limited in number due to access of biopsy samples, the volume of tissue analysed and the number of markers 
selected. Since this study was designed as a descriptive pilot study, a more focused analysis, using a few select 
markers building on the above results, would allow for an increased sample size and better statistical power. 
Secondly, areas for analysis were randomly selected in each high power field. This may well result in sampling 
error due to alteration of results should other areas have been sampled. Sampling bias was avoided by choosing 
the best representative area of naevus tissue in each section, regardless of staining intensity or proportion of 
positively labelled cells. This was continued in the same manner throughout the study and was conducted by a 
single observer. Lastly, a limited number of markers were utilised due to high costs of antibodies and their 
limited use in our laboratory. The best global marker was selected for each objective, however, a panel of 
markers for each objective may have provided improved results. Melanocyte precursor markers, such as MITF, 
c-Kit, TRP2, may have provided improved phenotypic characterization of naevus cells if used simultaneously. 
Similarly, additional neural crest markers, such as SOX10, TWIST and PAX3, and added pluripotency markers, 
such as SOX2, Alkaline phosphatase, SSEA-1 and SSEA-4, may have expanded on identification of precursor 
cells within naevus tissues.   
 
4.5 Conclusions 
This study demonstrates naevus cells display a melanocytic phenotype, due to the expression of melanocyte 
specific markers, and that this phenotype is consistent regardless of dermal depth. This strongly suggests that 
naevus cells arise from a melanocyte lineage. However, naevus cells show important phenotypic alterations and 
are morphologically distinct from differentiated melanocytes. Although studies have suggested regional 
variations in naevi and a possible Schwann cell lineage, there was no evidence in support of the existence of a 














Secondly, this data supports an epidermal origin of naevi. Proliferating naevus cells were most numerous in the 
epidermal compartment and this would suggest naevi are driven by epidermal proliferation. Discrete clusters of 
naevus cells were noted to occur at the tips of the rete ridges, separated by a normal intervening epidermis, and 
this would suggest naevi may have multiple sites of epidermal initiation. An epidermal origin of naevi would 
imply junctional naevi precede compound and then intradermal subtypes, in keeping with traditional models of 
naevus evolution and, in support of this, junctional naevi displayed an increased proliferative rate as compared 
to compound naevi, which further decreased in intradermal subtypes. A mechanistic hypothesis can therefore be 
proposed with evidence in support of an epidermal origin and subsequent “dropping off” of these cells into the 
dermis.  
 
It must be considered, however, that although the epidermis may drive naevus proliferation, it may not 
necessarily be the source of origin of the initiating cell. And, since this was a static, cross-sectional analysis, a 
mechanistic hypothesis cannot be credibly concluded. A dermal stem cell niche has previously been considered, 
based on the theory that the dermis would be less exposed to physiological or chemical stress than the epidermis 
(Li et al, 2009) and studies have demonstrated neural crest stem-like cells can be generated from dissociated 
dermis (Toma et al, 2001; Fernandes et al, 2004, 2008; Wong et al, 2006). In this study, precursor cells were 
present within the superficial dermis of naevus tissue and the hypothesis of an initiating cell within the 
superficial dermis, which subsequently migrates into the epidermis and/or reticular dermis, may also be 
proposed. Certain naevus samples showed merging of epidermal and dermal nests and/or a continuous dermal 
infiltration, without an epidermal element. Both the above would support the dermal expansion of naevus tissue 
from an initiating cell within the superficial dermis. 
 
Thirdly, this study convincingly demonstrates the presence of precursor or “stem” cells within naevus tissue. 
These cells were of both a pluripotent and neural crest phenotype. Dysplastic naevi contained the greatest 
proportion of precursor cells and it is hypothesised that this increased stem cell component may confer an 
increased risk of malignant transformation. Interestingly, pluripotency markers OCT4 and NANOG were not co-
expressed and thus pluripotent stem cells may exhibit temporal differences in the expression profiles of 
transcription factors in vivo. This may account for the discrepancies observed in previous studies of melanoma 
stem cells. Similarly, no OCT4 or NANOG positive cells were identified in the normal interfollicular epidermis 
of naevi or normal human skin. This implies that either these niche-resident cells down-regulate known stem 
cell markers, express other and/or currently unidentified stem cell markers, or do not exist.  
 
It was further noted that precursor cells were most numerous within the epidermal compartment of naevi. There 
was therefore an association between naevus proliferation and the presence of precursor cells. It is thus plausible 
that precursor cells drive naevus proliferation and it may be considered then that these stem-like cells give rise 













neoplasms. It is further proposed that cells with limited mutations would retain responses to normal micro-
environmental signals. Local proliferation would result in an expansion of cells which retain certain melanocytic 
differentiation pathways and remain within the epidermis, resulting in a junctional naevus. More severe 
mutations, or cumulative mutations, could result in an increased proliferative drive, a larger transit amplifying 
population and/or changes in adherence or response to micro-environmental signals. These cells could then 
migrate from the epidermis resulting in a compound, intradermal or dysplastic naevus; or a malignant 
melanoma. It is also plausible, however, that naevus cells result from differentiated melanocytes and, as they 
proliferate, they take on a more “un-differentiated” appearance and thereby resemble stem-like cells.  
 
Regardless of the aetiology of naevi, existing hypotheses imply naevus cells are able to migrate from one 
cutaneous compartment to another. Yet, benign cells, by definition, do not have the capacity to metastasize. To 
simplify this concept, a dual origin of naevi has been proposed. However, naevus cells have been demonstrated 
in regional lymph nodes (Biddle et al, 2003; Fontaine et al, 2002; Howel et al, 2006; Sewart and Copeland, 
1931) and in circulating blood (Argenziano et al, 2003; De Giorgi et al, 2010), and this phenomenon has been 
described as a benign metastatic process. It is hypothesized that a loosely adherent progenitor cell may enter the 
blood or lymphatic system, travel to distant sites and, if stimulated, may proliferate to form a naevus (Ross et al, 
2011) (Figure 39).  
 
Figure 39: Model of benign metastasis.  A melanocytic stem cell (1) undergoes an initiating event that transforms it into 
an immature naevus progenitor cell (2).  This cell (2) may remain quiescent until local environmental factors stimulate it to 
proliferate into a naevus (3).  Alternatively, this loosely adherent cell could enter the lymphatic system (4). Upon 
encountering a lymph node, the progenitor cell could either implant in the node and proliferate into a nodal naevus (5) or 
pass through without being sequestered (6) to eventually reach the circulatory system (7).  The progenitor cell would 
continue to circulate (8) until a transforming event, like a mutation, or environmental conditions signals the cell to implant 
in the skin (9).  The implanted naevus progenitor cell would remain quiescent in the skin until local environmental factors 
stimulate it to proliferate into a naevus (10) (Ross et al, 2011). 
 
This theory has been utilised to explain the occurrence of eruptive naevi (the sudden systemic development of 













nodes). This theory may similarly be used to explain melanoma development, the occurrence of satellite lesions 
in melanoma and the metastasis of malignant cells in general. This would support the tumour stem cell model of 
melanoma development. 
 
Lastly, it must be considered that not all melanocytic neoplasms necessarily originate in a similar manner. Blue 
naevi displayed important morphological differences to other naevus subtypes and appeared to have an 
associated epidermal proliferative abnormality with features more in keeping with that of a hamartoma. 
Junctional naevi appeared to have multiple sites of initiation, and this suggests the recruitment of many 
individual cells, while intradermal naevi showed a continuous infiltration of cells and was more suggestive of a 
single initiating cell. It is therefore possible that different mechanisms of pathogenesis may exist for different 
naevus subtypes. Certain subtypes may result from a local developmental abnormality, as supported by features 
of blue naevi and the occurrence of congenital naevi; others may develop following a local epidermal insult, 
such as changes in micro-environmental signalling and the generation of multiple simultaneous foci of initiation; 
while others may arise from a single mutated cell.  
 
Additionally, melanomas display different subtypes where some subtypes (such as the superficial spreading 
melanoma) are well accepted to be causally linked to cumulative ultraviolet radiation (UVR), while the 
contribution of UVR to the development of other subtypes (such as those occurring on the mucosa, acral areas 
or congenital melanomas) is less clear. In keeping with this, malignant blue naevi display different genetic 
mutations to those commonly observed in melanomas. Studies examining the presence and phenotype of 
melanoma stem cells have generated inconsistent results with some highly suggestive of a stem cell population 
which drives melanoma development (Fang et al, 2005; Grichnik et al, 2006; Klein et al, 2007; Schatton and 
Frank, 2008; Thies et al, 2004) and others showing a lack of evidence in support of melanoma stem cells (as 
reviewed by Girouard and Murphy 2011; Gupta et al, 2009 and Kennedy et al, 2007; Quintana et al, 2008, 
2010). It is highly plausible therefore that melanocytic neoplasms consist a heterogeneous group of disorders 
with altered mechanisms of initiation and development; and, while some neoplasms may originate from a 
mutated epidermal melanocyte and follow the traditional pathways of melanoma progression (Figure 3), others 
may well arise from a mutated tissue resident precursor cell, in support of the tumour stem cell hypothesis.  
 
4.6 Future directions 
This study provides strong evidence for the presence of precursor cells within naevus tissue. Their epidermal 
location and this association with naevus proliferation can reasonably be used to explain the development of 
naevi from a mutated tissue resident precursor cell, in support of the tumour stem cell hypothesis. However, this 
study provides only a static cross-sectional analysis of naevus tissue and the temporal development of naevi 
cannot be accurately concluded. It is entirely possible that these precursor cells result from differentiated 













temporal evolution of naevi are required to fully understand the aetiology and pathogenesis of melanocytic 
neoplasms, however, these prove difficult to execute. Also, further studies examining the possible molecular 
phenotype of stem cells in vivo, and the location of cutaneous stem cells niches, are required. Lastly, the 
relationship between cancer stem cells and adult stem cells needs to be explored. Information surrounding the 
process of de-differentiation, in order to fully understand this concept, as well as detailed mechanisms involved, 
may assist in supporting or disproving this concept and thereby assist in understanding the aetiopathogenesis of 
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6. Appendix A: Anatomical pathology reports 
Naevus sample 1 
 
Clinical details: 
? Melanoma. ? Naevus. 
  
Macroscopic: 
Specimen labelled “R side” consisting of an ellipse of skin measuring 12x7x7 mm. there is a 
pigmented macule measuring 5 mm in greatest dimension. The closest resection margin is less than 2 
mm.  
 
Anatomical site: thigh 
Lesions greatest dimension: 5 mm, additional dimension 0 mm 
Pigmentation: diffuse 
Edge: regular 
Satellite nodule (s): absent 
 
Microscopic: 
Sections show skin with only junctional nests of naevoid cells and focal basal hyperpigmentation. 
The papillary dermis shows mild mononuclear perivascular inflammation abundant melanin incontinence 
with scattered melanophages. There is no evidence of dysplasia or malignancy present. 
 
Diagnosis: 
Skin of thigh, excisional biopsy – Junctional naevus. 
 
Naevus sample 2 
 
Clinical details 
64 year old female. Naevus on back (left) – dark lesion, irregular border. Removed under LA. 
 
Macroscopic: 
Specimen labelled “back naevus” consists of a small ellipse of skin measuring 7x4x4 mm. There is a 




Sections of the skin biopsy show thin skin with occasional elongated rete ridges containing nests 
of bland melanocytes. Bridging of occasional rete ridges is also present. In addition, fibroplasia 
is noted. There is no pagetoid extension of the melanocytes. 
 
Diagnosis: 
Skin of back, excisional biopsy - features compatible with a Junctional naevus with mild atypia. 
 






Specimen labelled “left” thigh consists of an ellipse of skin measuring 18x10x4 mm with long suture 
superior, short suture medial. A 4 mm in diameter pigmented flat, non-ulcerated, rectangular lesion 
is present centrally, 2 mm from superior margin and 6 mm from the medial margin. Superior inked 
green and inferior black. Serially sliced into 3 mm slices from medial to lateral. 
 
Microscopic: 
Sections show a symmetrical melanocytic lesion with epidermal and intradermal nests of melanocytes. 
No atypia or dermal mitoses were seen. Melanocyte maturation is present toward the base of the 
lesion. The features are those of a benign compound naevus. The lesion is fully excised. 
 
Diagnosis 
Skin of (L) thigh, excisional biopsy - Compound naevus. 
 
Naevus sample 4 
 
Clinical details: 















Topographically unlabelled specimen consists of an ellipse of skin measuring 10x6x3 mm. The centre 
is hyperpigmented with a thin white rim. 
 
Microscopic: 
Sections of skin show nests of melanocytes in the dermis, with very scanty epidermal melanocytic 




Skin of foot, excisional biopsy - Benign compound naevus. 
 
Naevus sample 5 
 
Clinical details: 
Naevus of (R) buttock. ? Malignant melanoma. 
 
Macroscopic: 
Specimen labelled “biopsy” consists of a diamond of skin measuring 20x13x8 mm. A 6 mm pigmented 
lesion is visible on the surface. There is no suture to orientate the specimen.  
 
Microscopic: 
Sections of the buttock skin show: 
- A melanocytic lesion situated in the dermis 
- No junctional activity  
- Composed of benign appearing melanocytes 
- Melanin pigment in the neoplastic melanocytes and melanophages 
- A single mitosis is present 
 
Diagnosis: 
Skin of buttock, excisional biopsy - Benign intradermal naevus 
 
Naevus sample 6 
 
Clinical details: 
Tiny mole on anterior abdominal wall. Itch and increase in size recently. 
 
Macroscopic: 
Specimen consists of an ellipse of skin measuring 20x10 mm with underlying subcutaneous tissue 
measuring 20 mm in depth. A central 3 mm pigmented lesion is present 2 mm from the closest 
resection margin.  
 
Microscopic: 
Sections show a symmetrical lesion, composed of nests of naevus cells, predominantly in the dermis, 
with focal junctional activity. The dermal naevus cells show maturation toward the base of the 
lesion. No atypia or mitotic activity is present. 
 
The features are those of a predominantly intra-dermal naevus. The lesion is completely excised. 
 
Diagnosis 
Skin of anterior abdominal wall, excision biopsy – Benign intradermal naevus. 
 
Naevus sample 7 
 
Clinical details: 
? Melanoma. History of pencil lead / foreign body since childhood. 
 
Macroscopic: 
Specimen consists of skin excision right forearm 
State of specimen: fixative 
Dimensions of specimen: 12x7x3 mm 
Pigmented lesion: Regular, 5 mm circular 
Maximum diameter of dominant nodule: 5 mm 
Intactness of skin over the dominant nodule 
Minimum distance between the edge of the lesion and nearest resection margin: <1 mm 
 
Microscopic: 
Sections show a single fragment of skin with a dermal melanocytic lesion which is composed of 
dendritic melanocytes surrounded by dense collagen in the mid and upper dermis. There are some 
associated melanophages. 















Skin of right forearm, excisional biopsy - Blue naevus 
Naevus sample 8 
 
Clinical details: 
Pigmented lesion tip of nose. 
 
Macroscopic: 
Specimen consists of a pigmented nodular lesion with a diameter of 5 mm. specimen bisected. 
 
Microscopic: 
Section shows a cellular and heavily pigmented (requiring melanin bleach) dermal lesion composed of 
epithelioid and spindle/dendritic melanocytes which expand the dermis. The lesion is symmetrical 
and there are no features of ulceration or junctional melanocytic activity. No mitotic figures and 
no necrotic foci are identified. The Ki-67 immunochemical stain does not display significant 
nuclear immunoreactivity. The closest resection margin is 1 mm.  
 
There is no malignancy. 
 
Diagnosis 
Skin of nose, excision biopsy - Features compatible with a (epithelioid) blue naevus. 
 
Naevus sample 9 
 
Clinical details: 
Excision biopsy (R) abdomen. Marker medial. 
 
Macroscopic: 
Topographically unlabelled specimen consisting of an ellipse of skin measuring 15x8x3 mm with 
central pigmented lesion. The central lesion has an irregular edge measuring 9 mm in greatest 
dimension approximately 1 mm from the short resection margin. No marker is present. 
 
Microscopic: 
Multiple levels on this biopsy show collections of melanocytes in an atrophic epidermis and 
underlying superficial dermis. The nests are confined to the basal layer with no pagetoid spread. A 
small shoulder is present at the edge of the lesion. Rete pegs are fused with superficial lamellar 
dermal fibrosis. The dermal collections of melanocytes show pleomorphism, occasional atypical cells 
with prominent nucleoli. No mitotic figures could be found. 
 
Diagnosis 
Skin of (R) abdomen, excisional biopsy - The features are of a dysplastic (= atypical) naevus.  
 
Naevus sample 10 
 
Clinical details: 
Atypical naevus (L) calf. 
 
Macroscopic: 
Topographically unlabelled specimen received in fixative measuring 10x7x7 mm. pigmented lesion 
measures 9x6 mm. no dominant nodule. Intactness of skin over the nodule. Apices involved, side 
margins 0.5 mm. Bisected longitudinally. 
 
Microscopic: 
Histology shows intraepidermal lentiginous hyperplasia of melanocytes, occurring as single cells 
and in nests. There is hyperplasia and fusion of the rete pegs, often involving several pegs, and 
associated lamellar fibroplasias of the papillary dermis. There is a low grade cytological atypia 
of the epidermal melanocytes represented by focal hyperchromasia and nucleomegaly. The junctional 
component extends to the one apical resection margin. 
 
There is a dermal component of melanocytes that show poor maturation and similar low grade 
cytological atypia. The junctional activity extends beyond the dermal component (shoulder effect). 
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8. Appendix C – Immunofluorescence protocol 
 
Protocol for immunofluorescence of formalin-fixed paraffin embedded skin samples 
1. Place sections on hot plate for 15 minutes, or until was thoroughly melted 
2. Rehydrate sections according to standard protocol as follows: 
i. Xylol 2x 10 min 
ii. 100% alcohol 3x 3min 
iii. 90% alcohol 1x 1min 
iv. 70% alcohol 1x 1min 
v. Running tap water 1x 1min 
3. Antigen retrieval: Heat induced antigen retrieval (HIER) in pressure cooker 
i. Pre-heat pressure cooker, using water 
ii. Place 50 ml buffer solution in a coplin jar containing processed slides (≤ 4 slides per jar) 
iii. Place coplin jars in pre-heated pressure cooker: 
i. 0.01 M Citrate buffer (pH 6) for 20 minutes. Allowed to cool for 10 minutes. 
ii. 1 mM EDTA (pH 8) for 5 minutes . Allowed to cool for 10 minutes 
4. Wash slides in PBS 2x 5min 
i. Here washes in 1x PBS-Tween20 and 1x PBS-TritonX 100 may be tried if sub-optimal staining 
5. Dry slides and  placed in incubation chamber 
6. Block with 1% BSA in 1x PBS for 2 hours at room temperature 
7. Remove blocking solution and apply primary antibody  
i. Primary antibodies diluted in blocking solution (1% BSA in 1x PBS) 
ii. Dilutions optimised for each antibody  
iii. Dual staining – apply cocktail of primary antibodies, ensure end concentration of each antibody is correct 
iv. Incubate at 4 °C overnight in an incubation chamber 
8. Following day, wash slides in PBS 3x 5min 
9. Dry slides and apply secondary antibody 
i. Secondary antibodies diluted in blocking solution (1% BSA in 1x PBS) 
ii. Dilutions optimised for each secondary antibody (1:500 Alexa and 1:1000 Cy3)  
iii. Dual staining – apply cocktail of secondary antibodies, ensure end concentration of each antibody is 
correct 
10. Incubate at room temperature for 2 hours in an incubation chamber, in the dark 
11. Wash slides in PBS 3x 5min, in the dark 
12. Dry slides and mount using Mowiol  
13. Allow to dry at room temperature for a minimum of 1 hour, in the dark 
14. Store slides at 4 °C in the dark until viewed 
 
 
